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Dear Reader 
The following thesis is a composite of two separate research projects which were undertaken 
by the author for the award of an MRes in Molecular and Cellular Biology within the School 
of Biosciences at the University of Birmingham. 
Due to the different nature of each project it is hard to draw similarities between the two, 
although it is true that both may be of interest to a microbiologist as they both focus on 
microorganisms – Cryptococcus neoformans and Bdellovibrio bacteriovorus respectively. In 
addition to this both projects examine important proteins expressed by each organism which 
appear to contribute to their respective life cycles. 
Part one of this thesis will detail the first research project which sought to characterise the 
contribution of the enzyme phospholipase B to the intracellular lifecycle employed by the 
pathogenic fungus Cryptococcus neoformans which has the ability to survive within the 
phagolysosome of immune cell macrophages. 
Part two of this thesis switches kingdoms to detail the second project which examined the 
predatory bacterium Bdellovibrio bacteriovorus. This bacterium has a unique lifecycle which 
involves predation of other gram negative bacteria resulting in prey cell invasion and an 
interperiplasmic growth and replication phase. The aim of this project was to characterise the 
nature of two B. bacteriovorus proteins which alter the levels of the bacterial secondary 
messenger C-di-GMP which is thought to control aspects of the bacteria’s predatory lifecycle. 
As each part is so different in its target organism and methodologies it is understandable that 
the entire thesis may not be of professional interest to you, however it is hoped an 
appreciation of the thesis as a whole can nonetheless be found through a love of science and 
pursuit of new knowledge. 
Yours faithfully 
Robert Evans 
University of Birmingham 
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ABSTRACT - PART ONE 
How does the expression of phospholipase B influence the host pathogen relationship 
between Cryptococcus neoformans and the macrophage? 
Supervisor - Dr Robin C. May 
Cryptococcus neoformans is a pathogenic fungus that can cause fatal meningoencephalitis 
disease in immune compromised individuals. Fatal disease occurs when C. neoformans 
disseminates from the initial site of infection in the lungs to the central nervous system. 
Among the virulence factors which contribute to cryptococcal disease phospholipase B is the 
least understood. Phospholipase B is a phospholipid modifying enzyme, it currently has three 
confirmed enzymatic functions – phospholipase A1 activity, phospholipase A2 activity and 
lysophospholipase activity. Previous studies have revealed that phospholipase B is essential 
for full cryptococcal virulence. Phospholipase B has been implicated in multiple stages of 
cryptococcosis pathogenesis including intracellular survival within alveolar macrophages, 
escape from macrophages and dissemination to the central nervous system. In this study we 
sought to further characterise the phenotypes that phospholipase B deficiency produces in 
Cryptococcus neoformans. To do this we infected J774 murine macrophages with a 
phospholipase B knockout Cryptococcus neoformans var. grubii strain called PLB and 
compared the resulting infection phenotype with that of the wild type parent strain – H99. We 
found that phospholipase B is required for intracellular proliferation within macrophages. 
Phospholipase B deficiency also produces Cryptococcus cells which are larger in diameter 
than wild type cells. In this study we also report the first application of high throughput 
lipidomic analysis of Cryptococcus infected macrophages and identify a potential eicosanoid 
modifying treatment for Cryptococcus infection. 
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ABSTRACT- PART TWO 
An investigation into the properties of two Bdellovibrio bacteriovorus C-di-GMP metabolism 
proteins – Bd2325 and Bd1971 
Supervisor – Dr Andrew Lovering 
Bdellovibrio bacteriovorus is a small motile bacterium with a unique lifecycle; it has evolved 
to predate gram negative bacteria intracellularly, growing inside the prey cell periplasm. The 
predatory lifecycle of B. bacteriovorus is multifaceted and involves many distinct stages 
including prey cell recognition, attachment, cellular invasion, modification of prey cell 
structure, cellular replication and finally escape from the prey cell; each stage in the lifecycle 
appears to be tightly controlled by bacterial signalling cascades. At least some of the 
regulation within B. bacteriovorus is mediated by the small secondary messenger molecule C-
di-GMP which has come to prominence in the last few years as an important universal 
regulator of bacterial life processes such as controlling adhesion to surfaces, motility and the 
expression of virulence factors. The cytosolic level of C-di-GMP is controlled by the actions 
of two groups of opposing enzymes – guanylate cyclase GGDEF domain proteins synthesise 
C-di-GMP while phosphodiesterase EAL or HD-GYP domain proteins degrade C-di-GMP. In 
this study we attempt to discover the mechanism of signalling for two B. bacteriovorus 
phosphodiesterase proteins Bd2325 and Bd1971 – these proteins are a HD-GYP 
phosphodiesterase, and a EAL phosphodiesterase respectively. Determination of a crystal 
structure for these proteins would be invaluable to discover the function of these proteins and 
would aid B. bacteriovorus research and C-di-GMP signalling research greatly. Herein we 
report the refinement of recombinant expression and purification of each protein followed by 
preliminary biochemical analysis. 
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ABREVIATIONS 
Part one 
15d-PGJ2 - 15 deoxyΔ
12, 14
 prostaglandin J2 
AA – Arachidonic acid 
AIDS – Acquired immunodeficiency syndrome 
AML – Acute myeloid leukemia 
BAP – Bezafibrate and Medroxyprogesterone acetate combination treatment 
BEZ - Bezafibrate 
CD4 – Cluster of differentiation 4 
CFU – Colony forming unit 
CNS – Central nervous system 
COX-1 – Cyclooxygenase 1 
COX-2 – Cyclooxygenase 2 
DMEM – Dulbecco’s modified eagle medium 
DMSO – Dimethyl sulfoxide 
DPPC - Dipalmitoylphosphate 
FBS – Fetal bovine calf serum 
FT-ICR – Fourier transform ion cyclotron resonance 
GalXm - Galactoxymannan 
GxM - Glucuronoxymannan 
H99 – Cryptococcus neoformans wild type strain H99 – serotype A  
HIV – Human immunodeficiency virus 
HPLC – High performance liquid chromatography 
IL-12 – Interleukin -12 
IL-13 – Interleukin -13 
IL-4 – Interleukin - 4 
IPR – Intercellular proliferation rate 
LP - Lipoxin 
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LPL - Lysophospholipase 
LPTA – Lysophospholipid transacetylase 
LT - Leukotriene 
m/z – Mass charge ratio 
MPA – Medroxyprogesterone acetate 
PA - Glycerophosphate 
PBS – Phosphate buffered saline 
PCA – Principle component analysis 
PGA3 – Prostaglandin A3 
PGD2 – Prostaglandin D2 
PGE2 – Prostaglandin E2 
PGH2 – Prostaglandin H2 
PGJ3 – Prostaglandin J3 
PI - Glycerophosphoinisitol 
Pla1 – Phospholipase A1 
Pla2 – Phospholipase A2 
Plb – Phospholipase B 
PLB – Cryptococcus neoformans H99 strain with PLB1 knockout 
PLB1 - Cryptococcus neoformans PLB strain with PLB1 rescue version 1 
PLB2 - Cryptococcus neoformans PLB strain with PLB1 rescue – version 2 
PMA – Phorbol myristate acetate 
SF-DMEM – Serum free DMEM 
Th1 – T helper cell type 1 
Th2 – T helper cell type 2 
YPD – Yeast peptone dextrose media 
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Part two 
Ala – Alanine 
Asn - Asparagine 
Asp – Aspartic acid 
AUC – Analytical ultra centrifuge 
BBCF – Birmingham Biophysics Characterisation Facility 
BSA – Bovine serum albumin 
cAMP – Cyclic adenosine 3’,5’ monophosphate 
C-di-GMP – Bis- (3’5’)- cyclic dimeric guanosine monophosphate 
cGMP – Cyclic guanosine monophosphate 
CRP – cAMP receptor protein 
FPLC – Fast protein liquid chromatography 
FT – Flow through 
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GTP – Guanosine triphosphate 
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Tyr - Tyrosine 
UV - Ultraviolet 
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INTRODUCTION 
1.1 The Cryptococcus  family 
Cryptococcus neoformans is a pathogenic fungus belonging to the Basidiomycota phylum.   
C. neoformans is unusual among fungi in that it can cause serious disease in humans.  
Cryptococcal disease (also known as cryptococcosis) was first described over 100 years ago, 
but for many years remained relatively obscure as serious disease only occurred in individuals 
with existing immune deficiencies - which themselves were rare. In recent decades however 
the occurrence of cryptococcosis has risen. This is due mainly to the emergence and rapid 
spread of HIV AIDs as well as the growing use of immune suppressive drugs following organ 
transplant. These factors have contributed to a worldwide increase in the number of immune 
compromised hosts which C. neoformans can infect (Idnurm et al., 2005). A recent study 
estimated that cryptococcosis caused by C. neoformans could affect up to one million people 
worldwide annually and in sub-Saharan Africa where the HIV epidemic is most severely felt 
it could account for approximately 13-44% of HIV related deaths (Park et al., 2009). Recent 
years have also seen the emergence of a new cryptococcal species along the western 
seaboards of North American and Canada called Cryptococcus gatti which can cause fatal 
cryptococcosis in healthy, immune competent individuals (Bartlett et al., 2008).  
There are two sub varieties of Cryptococcus neoformans: C. neoformans var. neoformans and 
C. neoformans var. grubii, both C. neoformans varieties cause fatal cryptococcosis in immune 
compromised hosts.  Although C. neoformans infects humans it is primarily an environmental 
organism which can be isolated from the soil, bird guano and rotting wood (Kronstad et al., 
2011). Due to its yeast like nature C. neoformans is often compared to the laboratory yeast 
model Saccharomyces cerevisiae even though the two organisms are only distantly related 
evolutionary. C. neoformans can reproduce both sexually and asexually. Unlike asexual 
reproduction which occurs by budding, sexual reproduction involves a telomorph (a 
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taxonomical term used to define the sexual form of a normally asexual fungi) form called 
Filobasidiella neoformans. This telomorph state can form under certain environmental and 
nutritional conditions, genetic recombination occurs between two distinct mating types 
designated ‘a’ and ‘α’. This mating produces basidiospores which are thought to be the main 
infective vectors in cryptococcosis (Giles et al., 2009, Hull and Heitman, 2002) . 
1.2 Cryptococcus neoformans pathogenesis 
The pathogenesis of cryptococcosis begins in the lung following inhalation of live 
Cryptococcus cells or infectious spores (Giles et al., 2009). Infection most often occurs when 
individuals with an existing immune deficiency encounter C. neoformans in the 
environmental or come into contact with infected wild animals. Following inhalation the 
fungus colonises the lungs - in immune compromised hosts it then disseminates to the central 
nervous system (CNS) via the blood where it causes fatal meningoencephalitis. Healthy 
individuals who come into contact with C. neoformans can develop a latent infection which is 
confined to the lungs, if the infected hosts goes on to develop an immune deficiency in later 
life for example by contracting HIV then C. neoformans is able to emerge from its semi 
dormant state within the lungs and cause fatal disease (Garcia-Hermoso et al., 1999).  
The first immune defence C. neoformans encounters inside the lungs is the innate immune 
response. This response is characterised by activation of the complement cascade and the 
influx of innate phagocytic cells such as macrophages and neutrophils to the site of infection. 
Rather than being detrimental to C. neoformans survival in the lungs, the recruitment of 
alveolar macrophages to the site of cryptococcal infection is an important event in the life 
cycle of Cryptococcus infection.  Following phagocytosis C. neoformans is able to tolerate 
the destructive conditions inside alveolar macrophage and can even able replicate within the 
phagolysosome (Feldmesser et al., 2000).  
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Infection of the alveolar space by C. neoformans can manifest in both healthy and immune 
compromised hosts. In infected hosts who possess a working immune system C. neoformans 
is usually cleared from the lungs by the innate and later adaptive immune responses. However 
it is also possible for the infection to become chronic and remain within the lungs inside 
granulomatous formations similar to tuberculoid pathologies. The granulomas seen during 
cryptococcosis consist of clumps of alveolar macrophages which surround a core of 
extracellular cryptococci. Granuloma formation during C. neoformans infection is dependent 
on a CD4
+
 Th1 adaptive immune response (Hill, 1992). This may partly explain why HIV co 
infection correlates with poor granuloma formation and increased dissemination as HIV 
depletes a host’s CD4+ T cells. Although granuloma mediated trapping of C. neoformans can 
prevent dissemination to the CNS it also produces disease latency and could be responsible 
for the aforementioned observations that latent infections in healthy hosts can emerge as fatal 
cryptococcosis if an immune deficiency later develops. Evidence of this effect in a rat model 
of cryptococcosis showed that healthy rats infected with C. neoformans did not develop 
disseminated disease, instead the fungi was contained within alveolar granulomas. The 
Cryptococcus within the granulomas remained viable for up to 18 months post infection, 
when immune deficiency was mimicked using immune suppressive glucocorticoid steroids   
C. neoformans emerged from the granulomas and could disseminate to the CNS (Goldman et 
al., 2000).  
It is still not entirely clear how C. neoformans is able to disseminate from the lungs, into the 
blood and across the blood brain barrier into the brain. It is thought however that its ability to 
persist inside macrophages contributes in some way. Observations from our group (Ma et al., 
2006) as well as others (Alvarez and Casadevall, 2006) have noted that Cryptococcus has a 
unique method which it uses to escape from the macrophage. This mechanism termed 
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‘vomocytosis’ or ‘phagosomal extrusion’ allows Cryptococcus to jump out of the macrophage 
without any harm being done to itself or the host cell.  
The discovery of phagosomal extrusion supports the ‘Trojan horse’ hypothesis of 
cryptococcal dissemination which hypothesises that following phagocytosis in the lungs       
C. neoformans can survive and replicate within alveolar macrophages while using the niche to 
hide from immune detection. Infected macrophages from the lungs move to other parts of the 
body whereupon newly multiplied Cryptococcus cells jump from the macrophage into the 
extracellular space. As this escape does not harm the host cell it produces little inflammation, 
ensuring continued immune evasion. It is possible that C. neoformans emerge from their 
macrophage ‘Trojan horses’ when they are in circulation in the blood, the free C. neoformans 
cells can then cross the blood brain barrier themselves; which they have been seen to do 
(Chang et al., 2004). It is also possible however that some infected macrophages may cross 
into the CNS and deliver their cargo directly to their destination.  
1.3 Cryptococcus neoformans virulence factors 
Cryptococcus neoformans possesses several virulence factors which help it survive within the 
human body. These are production of a polysaccharide capsule, production of the pigment 
melanin, the ability to grow at human body temperature and secretion of environment 
modifying enzymes such as phospholipase B.  
Capsule expression 
The polysaccharide capsule surrounding C. neoformans is unusual for a fungus to possess. 
The capsule is implicated in virulence as capsule negative strains of Cryptococcus 
neoformans are avirulent (Fromtling et al., 1982, Chang and Kwon-Chung, 1994). The 
thickness of the capsule is dependent on strain genotype as well as growing conditions such as 
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environmental pH and CO2 levels (Granger et al., 1985).  Synthesis of the capsule is 
controlled by at least four genes designated CAP64, CAP59, CAP10 and CAP60 (Buchanan 
and Murphy, 1998, Ma and May, 2009) . Deletion of each  gene produces un encapsulated 
mutant which lack virulence (Chang et al., 1996, Chang and Kwon-Chung, 1994, Chang and 
Kwon-Chung, 1999, Chang and Kwon-Chung, 1998).The capsule is composed of two key 
polysaccharide components: glucuronoxylomannan (GXM) and galactoxymannan (GalXM) 
(Bose et al., 2003), with a ratio of approximately 9:1 by mass in favour of GXM (Idnurm et 
al., 2005).  
A number of survival benefits have been attributed to the possession of a capsule during 
cryptococcosis, for example it has been shown that the capsule can protect Cryptococcus 
neoformans from phagocytosis under certain conditions (Kozel and Gotschlich, 1982). 
Encapsulated Cryptococcus can be phagocytosed if they become opsonised however (Kozel 
and Gotschlich, 1982); but once phagocytosed the capsule is able to protect the yeast from 
destruction within the phagolysosome. Following phagocytosis C. neoformans cells produce 
thicker capsules; this adaption is thought to infer protection against intracellular conditions 
(Ma and May, 2009). During infection C. neoformans capsule size is at its largest in the lungs 
and becomes smaller in the brain (Rivera et al., 1998). Cryptococcus neoformans has also 
been reported to shed capsule polysaccharides such as GXM into the extracellular space. The 
polysaccharides are contained with vesicles which are expelled from the Cryptococcus in the 
extracellular space (Rodrigues et al., 2007). This GXM is thought to interfere with the 
generation of immune responses (Monari et al., 2006) 
37
o
C growth 
The ability to tolerate and even thrive at the human body temperature of 37 
o
C is important for 
any pathogen to cause long term infection. There are over 30 cryptococcal species which have 
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been identified but only two species Cryptococcus neoformans and Cryptococcus gatti are 
able to infect enough hosts to be considered serious threats to human health, one of the 
reasons for this is that these two species are able the only ones which can grow well at human 
body temperature e.g. 37 
o
C (Ma and May, 2009). In other words humans most likely come 
into contact with many other species of Cryptococcus but only C. neoformans and C. gatti 
have adaptations such as being able to grow at 37 
o
C which are required to colonise the 
human body.   
Melanin production 
C. neoformans has been found to produce the pigment melanin during in vivo infection (Rosas 
et al., 2000). Melanin synthesis has also been observed in strains isolated from pigeon guano 
(Nosanchuk et al., 1999). The study of un melanised Cryptococcus strains has revealed that 
melanin production has a role in virulence (Kwon-Chung and Rhodes, 1986). Melanisation is 
mainly thought to protect the fungus from macrophage killing as melanised cells are more 
resistant to radical oxygen species produced by macrophages. Melanisation also makes         
C. neoformans less susceptible to phagocytosis (Ma and May, 2009).   
Phospholipase B 
C. neoformans produces a secretory phospholipase called phospholipase B (Plb) which has 
been identified in several studies as an essential factor in cryptococcal virulence 
(Chayakulkeeree et al., 2011, Noverr et al., 2003, Chen et al., 1997a, Cox et al., 2001). Plb is 
a lipid modifying enzyme that has multiple catalytic functions. Plb possesses the catalytic 
functions of phospholipase A1 (Pla1) and phospholipase A2 (Pla2). Pla1 and Pla2 cleave the 
ester bonds which link the two fatty acid chains to the glycerol head in phospholipids at the 
sn1 and sn2 positions respectively; this produces a free fatty acid and a lysophospholipid. As 
Robert Evans 
7 
 
well as Pla1 and Pla2 activities Plb also has lysophospholipase (LPL) and lysophospholipid 
transacetylase (LPTA) activity. The LPL and LPTA activities both modify the 
lysophospholipid products of sn1 or sn2 cleavage. LPL removes the remaining fatty acid from 
the lysophospholipid to give a second free fatty acid and a glycerylphosphatidate whereas 
LPTA catalyses the formation of new phospholipid molecules by regenerating ester linkages 
between free fatty acids and lysophospholipids (Shea et al., 2006).  
The gene which codes for Plb is called PLB1; the gene is 2218 base pairs (bp) in length and is 
composed of 6 introns. PLB1 codes for a protein 637 amino acids in size. Homologous gene 
sequences to PLB1 have been found in other pathogenic yeasts such as Candida albicans 
(Cox et al., 2001) . The first complete purification and in-depth analysis of the Plb protein 
was published in by Chen et al. (Chen et al., 2000). The single protein they purified possessed 
all three enzymatic activities previously described. The mass of the protein was estimated to 
be around 160 kDa and was hypothesised to be composed of two equally weighted subunits. 
They also determined that its optimum pH for activity was in the acidic range; around 4.0 to 
5.0 pH and that the enzyme could function at 37 
o
C i.e. human body temperature.  Substrate 
analysis found that purified Plb could use a broad range of phospholipids as a substrate but 
dipalmitoylphosphates (DPPC) and phosphatidylglycerols (PG) were identified as preferred 
substrates (Chen et al., 2000). These properties suggest that Plb is bioactive within the body 
and more specifically within acidified phagolysosomes. When the PLB1 gene was isolated 
from C. neoformans it was speculated that the product was a secretory protein due to a stretch 
of hydrophobic amino acids which can indicate an extracellular localisation signature (Cox et 
al., 2001). This initial hypothesis has proved to be correct as secretion of Plb has been 
detected in clinical cases (Santangelo et al., 2005) as well as in vitro studies (Chen et al., 
1997b).  
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1.4 Phospholipase B and Cryptococcus neoformans pathogenesis 
Plb has been implicated as a contributor to C. neoformans virulence. For instance experiments 
from a murine cryptococcosis model found that mice infected with a Plb knockout strain of  
C. neoformans lived significantly longer than mice infected with a wild type H99 strain, in 
addition to this the Plb knockout strain produced a lower fungal burden in the lungs 
suggesting reduced survival and proliferation and a lower rate of dissemination to the brain, 
this final observation might correlate to a reduced rate of vomocytosis in Plb knockout strains 
which was also observed (Chayakulkeeree et al., 2011). These observations agree with other 
studies which have also noted that Plb deficient C. neoformans strains have reduced growth, 
dissemination and subsequent lethality in mice (Noverr et al., 2003, Chen et al., 1997a). 
There is some speculation over how Plb contributes to C. neoformans virulence. Plb can 
breakdown membrane lipids so potentially the enzyme could be secreted to destabilise the 
phagosome and outer membrane of the host cell, this explanation is unsatisfactory however 
because C. neoformans is able to survive and grow sufficiently well inside the phagosome and 
does not disrupt phagosome maturation (Levitz et al., 1999). Furthermore vomocytosis from 
the macrophage does not cause harm to macrophage (Ma et al., 2006) which probably would 
occur if its cell membrane was damaged in any way in the process.  
Another theory is that Plb activity metabolises either Cryptococcus or macrophage derived 
phospholipids and produces arachidonic acid (AA). This lipid metabolite sits at the top of the 
eicosanoid synthesis pathway. Members of the eicosanoid family include prostaglandins (PG), 
leukotrienes (LT) and lipoxins (LP). Eicosanoids are lipid derived signalling molecules which 
have roles in cell signalling. These signalling molecules are of special note in the case of C. 
neoformans parasitism of host immune cells as there is in depth and conclusive evidence that 
eicosanoids are key modulators of the host immune response (Harizi et al., 2008).  
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Each eicosanoid subtype is produced by the modification of AA via a specific enzyme, for 
example the PG pathway specific precursor PGH2  is produced by the oxidation of AA by the 
cyclooxygenase enzymes COX-1 and COX-2 whereas LT and LP specific precursors are 
produced by two different lipoxygenases. Eicosanoid production is unregulated during 
inflammation, especially PG synthesis via the up regulation of COX-2 (Harizi et al., 2008). In 
the model proposed arachidonic acid is liberated by Plb from possibly the cryptococcal 
membrane, phagosomal membrane, macrophage outer cell membrane or possibly other 
membrane bound organelles in the macrophage. The increased amount of arachidonic acid 
consequently contributes to increased eicosanoid production. The proposed origin of these 
extra eicosanoids is as unknown as the site of arachidonic acid liberation. Both macrophages 
(Harizi et al., 2008) and C. neoformans itself (Noverr et al., 2001) can produce eicosanoids so 
either or both may contribute. Eicosanoids exert their effects largely on the cells which 
produce them via autocrine signalling and to a lesser extent via paracrine signalling so the 
production of eicosanoids by infected macrophages likely influences only these cells or cells 
in close proximity (Harizi et al., 2008).  
Eicosanoids might aid C. neoformans survival by attenuating or suppressing the antimicrobial 
mechanisms of the infected macrophage, but they may also influence the nature of the broader 
immune response produced during cryptococcosis. For example PGE2 which is one of the 
most ubiquitous prostaglandins during inflammation can produce a Th2 CD4
+
 biased immune 
response by down regulating IL-12 release from macrophages (van der Pouw Kraan et al., 
1995). With this in mind previous findings from our group have shown that C. neoformans 
inside J774 macrophages in the presence of Th2 cytokines such as IL-4 and IL-13 show 
increased proliferation and cellular escape compared to untreated macrophages and those 
treated with Th1 cytokines (Voelz et al., 2009). 
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1.5 Project aims 
Studies from our group and others have shown that knockout strains of C. neoformans 
deficient in Plb show reduced virulence. We wish to further characterise this attenuation in the 
hope that we can further understand the role that Plb plays in cryptococcosis. We will assess 
how well a PLB1 knockout of C. neoformans var. grubii (H99) can survive within a murine 
J774 macrophage cell line. We will compare this knockout strain to a wild type H99 and a 
knockout strain which has had the PLB1 gene artificially reconstituted via a plasmid vector. 
As well as these virulence assays we will also start to unravel the complex network of lipid 
metabolism found inside a macrophage infected with Cryptococcus. In what we believe to be 
the first  application of high throughput lipidomic technology to analyse macrophages 
infected with Cryptococcus we will utilise electrospray Fourier transport ion cyclotron 
resonance (FT-ICR) mass spectrometry to analyse whole cell lipid extractions from 
macrophages infected with wild type H99 and Plb knockout C. neoformans. From the lipid 
identity profiles produced we hope to begin to deduce what lipids Plb may be modifying 
during infection.  
Robert Evans 
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MATERIALS AND METHODS 
2.1 Cells and strains 
As an in vitro macrophage model we used a murine J774 macrophage cell line.  
C. neoformans var. grubii strain H99 was the wild type Cryptococcus strain used in our study; 
PLB, PLB1 and PLB2 are genetic mutants derived from H99. The creation of PLB, PLB1 and 
PLB2 has been described in detail previously (Cox et al., 2001). Briefly the PLB knockout 
strain was created by disrupting the PLB1 gene using insertion while the two rescue strains – 
PLB1 and PLB2, both had Plb activity restored with a plasmid vector containing an intact 
PLB1 gene. PLB1 and PLB2 represent the two most successful transformant strains created 
e.g. they showed restored Plb activity and otherwise almost identical behaviour to the wild 
type strain. 
Cryptococcus neoformans strains (H99, PLB, PLB1, PlB2) from our strain library which is 
stored at -80 
o
C were streaked onto YPD agar (1 % Yeast extract – MP cat no# 103303, 1 % 
peptone - Melford cat no# GP1328, 2 % dextrose – Fisher Scientific cat no# G/0500/53, 2 % 
Agar – Melford cat no# m1002) and grown for 48 hours at 25 oC and then stored until needed 
at 4 
o
C to halt further growth. Before experimentation liquid cultures were grown from these 
stock plates in 2 ml YPD growth medium (1 % yeast extract, 1 % peptone, 2 % dextrose) ) in 
14 ml PP test tubes ( Greiner BioOne cat no# 187261) for 24 hours at 25 
o
C while constantly 
being rotated to ensure complete cell suspension during growth. 
2.2 Intracellular proliferation assay 
J774 preparation 
J774 cells were grown to approximately 70 % confluence in T75 tissue culture flasks (Cat no# 
178905, Nunc – Thermo Scientific)  with complete DMEM ( Dulbecco’s Modified Eagle 
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medium, low glucose, Sigma Aldrich Cat no# D5546, supplemented with 10 % FBS - 
Invitrogen, 1%  10,000 units Penicillin / 10 mg streptomycin – Sigma cat no# 4333-100ml , 1 
% 200 mM L – glutamine – Sigma cat no# G7513) before being re-plated into 2 cm2 24 well 
tissue culture plates (Greiner BioOne Cell Star – cat no# 662160)  at a density of 1x105 cells 
per well in 1 ml complete DMEM. The plates were then incubated for 24 hours at 37 
o
C, 5 % 
CO2. 
C. neoformans cells preparation 
Overnight 2 ml cultures of each C. neoformans strain were grown as previously described. 
After 24 hours of growth the 14 ml tubes were vortexed to ensure complete resuspension of 
cells before aliquoting 1 ml from each culture into separate autoclaved 1.5 ml Eppendorf 
tubes. To wash the cells each tube was centrifuged for 2.5 minutes at 6500 rpm (MSE 
centrifuge), following centrifuging the supernatant was discarded. The pellet containing the 
Cryptococcus cells was then resuspended in 1ml sterile PBS (Sigma Aldrich cat no# P4417).  
The number of cells for each strain was calculated by counting with a haemocytometer before 
making dilutions of 1x10
6
 cells per 100 μl PBS in 1.5 ml Eppendorf tubes, making enough 
dilution to give 100 μl per well required in the IPR. An hour before infection 0.1μl opsonising 
antibody (18B7, an IgG capsular polysaccharide monoclonal antibody – kindly provided by 
Arturo Casadevall, Albert Einstein College of Medicine, New York , USA)  per 100 μl was 
added to each tube. The tubes were then left for 1 hour in a rotator at room temperature. 
J774 activation and infection 
Unless otherwise stated the J774 macrophages were activated before infection via treatment 
with PMA (phorbol myristate acetate). Briefly the medium from each well was removed and 
replaced with 1ml fresh serum free DMEM supplemented with 15 μl 10 μg/L phorbol 12-
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myristate 13-acetate (PMA) (Sigma Aldrich cat no# P1585 , stock concentration 1 mg/L 
resuspended in DMSO (dimethyl sulfoxide – Sigma Aldrich cat no# D454400-100 ml ) 
diluted from stock concentration with sterile PBS. After 45 minutes of exposure the PMA 
supplemented medium was removed from each well and replaced with serum free DMEM (SF 
DMEM) (The same composition as complete DMEM but without 10 % FBS) 
Following a two hour incubation the medium from each well was aspirated away. To remove 
any remaining un-phagocytosed Cryptococcus each well was washed 4 times. To do this 1ml 
of sterile PBS was added to each empty well before gently tapping the sides of the culture 
plate to agitate any non adherent cells; the PBS was then quickly aspirated away. This wash 
was repeated at least four times for each well. Between each was the number of remaining 
extracellular yeast cells was assessed under a microscope. Four washes was usually sufficient 
to remove all extracellular yeast, however more washes were applied if needed. Following the 
last wash the PBS in each was replaced with 1 ml SF DMEM. 
Counting 
Before counting the medium was removed from the wells for the corresponding time point. 
Each well was washed twice with 1 ml PBS agitating in between washes to remove 
extracellular yeast. To lyse the macrophages and release the intracellular Cryptococcus for 
counting 200 μl distilled water was pipetted into each well, the plate was then incubated for 
25 minutes. Following cell lysis the bottom surface of each well was scraped with the end of a 
pipette tip before removing the distilled water and transferring it to a 1.5 ml Eppendorf tube. 
Each well was washed out with an addition 200 μl of distilled water to ensure all the yeast 
was collected. The cells were then counted by eye using a haemocytometer. 
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2.3 Cell size assay 
Setup for the cell size assay was identical to the intracellular assay. J774 cells were plates at a 
concentration of 1x10
5
 cells per well, activated with PMA for 45 minutes, infected with     
100 μl opsonised C. neoformans (1x106 cells) , incubated for 2 hours at 37 oC, washed four 
times with PBS and refreshed with 1ml SF DMEM as previously described. 
The plate was placed in an environmentally controlled stage (Okolabs) set to 30 
o
C, 5 % CO2.  
The cells were imaged using a Nikon TE2000 microscope attached to a Digital Sight DS-
Qi1MC camera. Bright field microscopy was used with a 20 x objective lens (Ph1 PLAN 
APO). Three positions were chosen for each experimental condition and a time lapse movie 
was created from each position. Frames were recorded every 4 minutes for 20 hours. Image 
acquisition and analysis was performed using the Nikon Elements software package (Nikon). 
Cell size was measured using the ellipse area tool found on Nikon Elements (Nikon), a perfect 
circle was drawn from the centre of each Cryptococcus cell, the size of the circle was 
determined by the first edge of the area circle to hit the edge of the cryptococcal cell boundary 
– Cryptococcus cells are normally circular but are not always perfect circles, this regime 
sought to standardise measurement of irregular shaped cells. Cell diameter was recorded in 
pixels; this measurement was converted to μm using the appropriate calibration for the 20x 
lens (1 pixel  0.461 μm). 
Statistical analysis 
A non parametric Mann Whitney U test was performed to calculate the significance of size 
distribution shift for each experiment (e.g. StrainX 0 hour vs. StrainX 18 hour). The analysis 
was performed using an online tool (http://faculty.vassar.edu/lowry/utest.html). A 
measurement of significance was given as a Z value. The α value was 0.05 meaning that any 
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Z value below -1.95 or above 1.95 was considered to be significant. A two tailed T test was 
also calculated to give a P value.  
2.4 Lipidomics study 
Cell preparation 
The preparation of infected J774 cells for the lipid extraction was similar to the preparation of 
the intracellular proliferation and vomocytosis assays previously described but on a larger 
scale. Instead of growing macrophages in 2 cm
2
 24 tissue culture plate wells the cells for each 
experimental condition were grown in T75 flat bottomed tissue culture flasks. Before the start 
of the study the cells were grown to around 80 % confluence which we estimated would give 
a total cell number in the flask of around 4x10
6
 per flask. The macrophages were activated 
with PMA 45 minutes before infection with 4x10
7
 opsonised Cryptococcus. After two hours 
un phagocytosed cells were washed away and the medium was replaced with serum free 
DMEM. The flasks were then incubated for 24 hours at 37 
o
C, 5 % CO2. 
Cell quenching 
Following a 24 hour incubation period each flask was taken in turn from the incubator and 
washed twice with 10 ml PBS to remove any extracellular cryptococcal cells which may have 
emerged due to macrophage lysis or cellular escape. All of the PBS between washes was 
removed using a glass Pasteur pipette, making sure to tilt the flask so that all of the remaining 
PBS collected in one corner before removing. 
Next 2 ml of the extraction solution (60 % HPLC grade methanol, 40 % HPLC grade distilled 
water) which had been chilled in dry ice for at least 15 minutes was added to each flask. After 
addition the adherent cells in the flask were scraped from the surface of the flask using a cell 
scraper. To ensure low temperatures at this stage the flasks were placed on a thin layer of dry 
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ice during the scraping. The cells were transferred to pre chilled (at least 15 minutes in dry 
ice) 2 ml Eppendorf tubes using a clean glass Pasteur pipette. Until all of the flasks were 
processed each tube was kept chilled in dry ice to prevent metabolic activity. The tubes were 
then centrifuged with a fixed angle rotor (Thermo Scientific cat) for 5 minutes at 2500 g 
(Heraeus Biofuge primo R, Thermo Scientific). To keep the temperature of this stage under   
0 
o
C the centrifuge was pre-chilled to -9 
o
C and the fixed angle rotor was placed in a -20 
o
C 
freezer for at least an hour before use. In addition to pre-chilling the centrifuge care was taken 
not to overcrowd and potentially heat the centrifuge – a limit of 10 tubes per spin was 
imposed.  
The supernatant was removed from the tubes using a glass Pasteur pipette and discarded and 
the remaining pellets were stored at -80 
o
C until extraction. 
Lipid extraction 
The weight of each cell pellet was calculated by subtracting the weight of the 2 ml Eppendorf 
tube pre experiment from the final weight. 8 µl methanol (HPLC grade) per mg of the cell 
pellet weight was added to each tube. 8 µl chloroform (HPLC grade) per pellet mg was added 
to clean 1.8 ml glass vials, the resuspended contents of each 2 ml Eppendorf tube were then 
transferred to these vials using a clean glass Pasteur pipette for each transfer. Following 
transfer the methanol and chloroform mix was taken back up into the pipette and ejected into 
the vial twice to rinse out any remaining residue within the pipette. 7.2 µl distilled water 
(HPLC grade) per mg was then added to each vial. The vials were then vortexed for 30 
seconds each and left on ice for 10 minutes. After 10 minutes the samples were loaded into a 
spinning bucket centrifuge (Heraeus, Thermo Scientific) and spun for 10 minutes at 1500 g,   
4 
o
C.  After centrifugation the vials were carefully removed from the centrifuge and left to rest 
for 5 minutes. After the samples have settled there should be three distinct layers, the upper 
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layer containing polar metabolites, the middle interface layer proteins and the lower layer non 
polar lipids.  
Using a Hamilton syringe (Hamilton) two 200 µl aliquots from the top polar layer were 
removed into 1.5 ml Eppendorf tubes, washing before each use with methanol. The syringe 
was then washed out with chloroform and as much of the lower non polar was removed and 
transferred to a clean 1.8 ml glass vial. Care was taken not to disturb the interface layer. The 
syringe was washed with chloroform between each use. The polar and non polar samples as 
well as the original vials with the remaining interface were stored until needed at -80 
o
C. 
Non polar sample mass spectrometer analysis  
Before analysis 60 µl aliquots of each non polar sample were made from the vials in -80 
o
C 
storage into clean 1.8 ml glass vials. The samples were dried under liquid nitrogen before 
being resuspended with 120 µl of a methanol and chloroform mixture (2:1 ratio respectively) 
supplemented with 5 mM ammonium acetate. Each sample was then vortexted for 30 seconds 
to fully re suspend.  
Just before the loading of the 96 well sample plate the samples were centrifuged for 10 
minutes at 4 
o
C to remove particulate contamination. Being careful not to disturb the samples 
after centrifuging 11 µl aliquots were pipetted into each well of the 96 well sample plate.    
Data Collection 
To analyse the samples and process the raw data we were kindly assisted by Dr Andy 
Southam, a post doctoral research assistant who works with Professor Chris Bunce, School of 
Biosciences, Birmingham University. 
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In total 6 non polar samples were analysed for the pilot study. This sample set included two 
strains – H99 and PLB and there were three repeats for each strain. In addition to the six 
samples a blank sample was analysed. This blank sample was composed of just the solvents 
used in the previous non polar sample preparation step (e.g. 2:1 ratio methanol and 
chloroform with 5 mM ammonium acetate. 
The samples were analysed in triplicate using a high resolution FT-ICR mass spectrometer 
(model: LTQ-FT ultra, Thermo Scientific) attached to a nano electrospray sample infuser 
(Model: Triversa, Advion Biosciences). The raw data was collected as transient scans of the 
detected signals.  
Data pre-processing 
Following sample analysis the raw transient scan data was averaged and was converted into a 
conventional mass spectrum dataset (e.g. m/z vs. intensity) using a Fourier transform 
algorithm with the MATLAB software package. 
Data Processing 
To process the data it was first filtered so that only peaks which were found in at least 2 out of 
3 triplicate samples were counted as real, any peaks failing this criteria were discarded as 
noise. A matrix was generated to display the triplicate filtered samples data, comparing m/z 
with the relative intensity reading for each sample, only peaks which had an intensity > 0 in at 
least 50% of the samples were included within the matrix. In addition to this any peaks which 
were detected within the sample set as well as the blank were considered contamination and 
as such were omitted from the matrix. Finally the matrix was normalised using PQN 
normalisation.    
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Bezafibrate (BEZ) and medroxyprogesterone (MPA) combination treatment 
The intracellular proliferation assay itself was performed as previous described; however the 
assay used only H99 and PLB strains. The two strains were split into two treatment groups, 
H99 and PLB without BAP treatment and H99 and PLB with BEZ and MPA (BAP) 
treatment. Time points were measured at 0 hour, 18 hour and 24 hour time points. 
BEZ (stock concentration 0.05 M, diluted in DMSO)  and MPA (stock concentration 0.5 mM, 
diluted in ethanol) was added to each treatment well following infection with Cryptococcus at 
a concentration of 1 in 1000 (e.g. 1 µl BEZ and 1 µl MPA per 1000 µl) (Both drugs were 
kindly provided by Professor Chris Bunce, University of Birmingham) Following washing 
with PBS after infection the new serum free DMEM medium was re supplemented with BAP 
at the same concentrations as before. 
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RESULTS 
3.1 Phospholipase B is required for in vitro cryptococcal intracellular growth.  
Previous studies have reported that PLB1 deficient C. neoformans have an altered phenotype 
from the wild type that importantly procures reduced virulence. For example in vivo 
experiments in have mice have shown that mice infected nasally with PLB1 knockout mutants 
have a reduced fungal load in the lungs as evidenced by a decreased number of recoverable 
CFUs over time compared to wild type strains (Chayakulkeeree et al., 2011).  
C. neoformans infection in the lung is mainly localised inside macrophages. For this reason 
we hypothesised that decreased fungal burden in the lungs of mice was due to an intracellular 
growth deficiency caused by PLB1 knockout. To test this we performed a macrophage 
intracellular proliferation assay with PMA activated J774 murine macrophages and opsonised 
H99, PLB, PLB1 and PLB2 Cryptococcus strains. The number of intracellular C. neoformans 
was calculated for each strain at 0 hour, 18 hour and 24 hour time points. The maximum 
intracellular burden (usually at 18 hours) was divided by the initial intracellular burden 
counted at 0 hours. This calculation gives the ‘IPR’ or intracellular proliferation rate. To 
examine the IPR values for each strain we chose to pre activate the J774 cells with PMA. 
PMA activation makes the behaviour of the macrophages more consistent as they are all 
activated to a similar level; thus any differences in IPR seen between strains could be more 
confidently attributed to differences between the strains and not variations in macrophage 
state. 
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Figure 1: IPR assay with PMA activated J774 macrophages - The intracellular 
proliferation rates of C. neoformans stains H99 (wild type, PLB parent), PLB (PLB1 
knockout), PLB1 and PLB2 (PLB1 knockout rescues) inside PMA activated J774 macrophage 
cells were measured using an intracellular proliferation rate (IPR) assay. Briefly 1x10
6
 18B7 
opsonised C. neoformans was added to 1x10
5
 PMA activated J774 macrophages plated in 24 
well tissue culture plates in 1ml serum free DMEM. After two hours (0 hours) extracellular 
Cryptococcus cells were washed away, the number of intracellular Cryptococcus were 
counted at 0, 18 and 24 hour time points. The IPR was calculated from the maximum 
intracellular cell number divided by the initial uptake at 0 hour. Filled in bars represent the 
mean IPR value for each strain (n=5), error bars represent 2x standard error. A two tailed 
Student’s t test was performed for the following groups: H99 vs. PLB (* P= 0.01) H99 vs. 
PLB1 (** P= 0.64), H99 vs. PLB2 (*** P= 0.95) and PLB1 vs. PLB2 (**** P=0.63) values 
below 0.05 are considered significant. 
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Comparing the IPR for the wild type strain H99 to the knockout mutant PLB (Figure 1) we 
saw a significant (P= 0.01) decrease in intracellular proliferation of over 50 % for the 
knockout IPR. As well as H99 and PLB we also analysed two PLB rescues (PLB1 and PLB2) 
which have the PLB1 gene artificially reintroduced. The IPR results for PLB1 and PLB2 were 
not significantly different from H99 (P= 0.64 and P= 0.95 respectively) or from each other   
(P = 0.65) which suggests that the knockout of PLB1 is responsible for the proliferative 
deficiency seen in the knockout. Taken together these observations suggest that knockout of 
the PLB1 gene produces a cryptococcal phenotype that is less suited to intracellular 
proliferation than the wild type or knockout rescue strains. 
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Figure 2: IPR assay with un-activated (no PMA) J774 macrophages - The intracellular 
proliferation rates of C. neoformans stains H99 (wild type, PLB parent), PLB (PLB1 
knockout), PLB1 and PLB2 (PLB1 knockout rescues) inside un-activated (not PMA pre-
activated) J774 macrophage cells were measured using an intracellular proliferation rate 
(IPR) assay. Briefly 1x10
6
 18B7 opsonised C. neoformans was added to 1x10
5
 un activated 
J774 macrophages plated in 24 well tissue culture plates in 1ml serum free DMEM. After two 
hours (0 hours) extracellular Cryptococcus cells were washed away, the number of 
intracellular Cryptococcus were counted at 0, 18 and 24 hour time points. The IPR was 
calculated from the maximum intracellular cell number divided by the initial uptake at 0 
hour. Filled in bars represent the mean IPR value for each strain (n=6), error bars represent 
2x standard error. A two tailed Student’s t test was performed for the following groups: H99 
vs. PLB (* P= 0.04) H99 vs. PLB1 (** P= 0.19), H99 vs. PLB2 (*** P= 0.24) and PLB1 vs. 
PLB2 (**** P=0.77) values below 0.05 are considered significant. 
0.00 
0.50 
1.00 
1.50 
2.00 
2.50 
3.00 
3.50 
4.00 
4.50 
5.00 
H99 PLB PLB2 PLB1 
M
ea
n
 I
P
R
 
Strain 
* 
** 
*** 
**** 
Robert Evans 
24 
 
Activation of macrophages with PMA is an efficient experimental procedure to create 
conformity within a culture; however it is not a physiological stimulus and in fact produces a 
very extreme activation state. For these reasons we wanted to confirm that proliferative 
phenotype displayed by PLB was not an artefact of our experimental conditions, thus we 
repeated the previous IPR experiment but used J774 macrophages which were not pre 
activated with PMA (Figure 2). Without PMA activation we saw the same trend that we found 
with PMA activation; H99, PLB1 and PLB2 showed no significant difference in intracellular 
proliferation whereas in comparison PLB showed a significant decrease (P= 0.04) in 
intracellular proliferation. This suggests that the PLB proliferation deficiency seen in 
activated J774 cells (Figure 1) still occurs in un activated J774 cells (Figure 2), and thus is not 
a result of PMA activation. 
Previous experiments in our lab have shown a correlation between initial uptake (0hr) and the 
resultant IPR (data unpublished). This correlation suggests that high uptake usually results in 
a lower IPR and vice versa. We noticed that the initial uptake at 0hr for PLB was higher than 
the other strains. This was seen especially following PMA pre activation. We found that PMA 
activation while producing a general increase in initial uptake across all strains boosted the 
uptake of PLB most significantly. In view of these observations we wondered whether the 
IPR for PLB was low due to its initial high uptake – we theorised that a high initial uptake 
could overcrowd macrophages and produce an environment where conditions for C. 
neoformans growth was unfavourable. 
To investigate whether the PLB mutant’s low proliferative capacity was linked to its high 
initial uptake we repeated the IPR assay but did not opsonise the C. neoformans we used to 
infect the macrophages. The efficiency of C. neoformans phagocytosis is reduced when the 
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Cryptococcus are not opsonised; thus by infecting the macrophages with un-opsonised 
Cryptococcus we were able to reduce the uptake.  
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Figure 3A: IPR assay with un opsonised Cryptococcus strains- The intracellular proliferation 
rates of un-opsonised C. neoformans stains H99 (wild type, PLB parent), PLB (PLB1 knockout), 
PLB1 and PLB2 (PLB1 knockout rescues) inside activated J774 macrophage cells were 
measured using an intracellular proliferation rate (IPR) assay. Briefly 1x10
6
 un opsonised C. 
neoformans was added to 1x10
5
 PMA activated J774 macrophages plated in 24 well tissue 
culture plates in 1ml serum free DMEM. After two hours (0 hours) extracellular Cryptococcus 
cells were washed away, the number of intracellular Cryptococcus were counted at 0, 18 and 24 
hour time points. The IPR was calculated from the maximum intracellular cell number divided by 
the initial uptake at 0 hour. Filled in bars represent the mean IPR value for each strain (n=3), 
error bars represent 2x standard error. A two tailed Student’s t test was performed for the 
following groups: n=3, H99 vs. PLB (* P= 0.01) H99 vs. PLB1 (** P= 0.43), H99 vs. PLB2 (*** 
P= 0.56) and PLB1 vs. PLB2 (**** P=0.30) values below 0.05 are considered significant. 
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Figure 3B-I to 3B-III: Scatter plots showing the relationship between initial uptake (0 
hr) and the resulting IPR – Scatter plots for each IPR assay – with PMA (Bi), without PMA 
(B-ii) and with no opsonisation (B-iii) were drawn to compare the initial uptake at 0 hr (X 
axis) with the resulting IPR (Y axis), for each plot the blue diamonds represent H99, the red 
squares represent PLB, the green triangles represent PLB1 and the grey crosses represent 
PLB2. 
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The use of un-opsonised yeast reduced the initial uptake at 0 hr for all four strains (Figure 3 
B-III) compared to the previous IPR experiments using PMA activated (Figure 3 Bi ) and un-
activated macrophages (Figure 3 B-iii). In the case of PLB the initial uptake count at 0 hr was 
reduced by about 50% compared to the first IPR with activated macrophages (Figure 3 B-i 
and B-iii). Although the uptake was reduced the IPR values for un-opsonised PLB (Figure 3 
A) was not significantly different (P = 0.57) from the IPR values obtained with opsonisation 
and PMA activation (Figure 1). This data suggests that deficiency in intracellular growth is 
still present when the uptake is reduced and thus the deficiency does not seem to be uptake 
dependant.  
As a whole (Figures 1 – 3) our IPR data identifies a possible proliferation deficiency for PLB 
which is not seen for H99, PLB1 or PLB2 strains. This suggests that deficiency in Plb 
expression in C. neoformans leads to an aberration in proliferative ability inside infected J774 
macrophages. 
3.2 PLB1 knockout produces a distinct, much larger cellular morphology in PLB .  
While performing the IPR experiments we observed that PLB was unique among the strains 
tested in that the physical size of the knockout cells seemed to increase with time; this growth 
in cell size was not observed for H99 or PLB1 and PLB2.  
We wished to quantify this growth in size as we realised that a diversion of energy from cell 
budding to cell expansion may be an explanation for why PLB appears to proliferate poorly in 
J774 macrophages. In addition to this an increase in C. neoformans cell diameter has 
previously been reported during in vivo infection, it was suggested that this growth may help 
protect C. neoformans against immune defences during infection but as a trade off the larger 
size diminishes cryptococcal dissemination from the lungs to the brain (Okagaki et al., 2010). 
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To quantify the change in C. neoformans cell size over time we imaged infected J774 cells 
using bright field live cell microscopy to create time lapse movies which tracked the 
expansion of C. neoformans cells within macrophages. For this experiment we chose to 
analyse only one of the rescues – PLB2 to compare with H99 and PLB1. The decision to 
exclude PLB1 was made following the first experiment.  Although we saw that both rescues 
PLB1 and PLB2 behave like the wild type PLB2 was potentially more like H99 than PLB1. 
The diameter of all intracellular C. neoformans cells in three repeats was measured at 0 hours 
(2 hours post infection) and 18 hours; two replicates were analysed per strain, per repeat. To 
avoid counting bias all the intracellular C. neoformans cells within a position were counted. 
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Figure 4 A – Frequency distribution histograms of C. neoformans cell diameter – The 
diameter of C. neoformans cells inside infected macrophages (Strain – J774: A-i to A-iii) and 
in serum free DMEM (Strain –DMEM: A-iv to A-vi) was measured using the ellipse circle 
measurement tool on NIS elements – the cell diameter was measured in pixels which was then 
later converted to µm using the appropriate calibration for the 20 X lens used. Overlapping 
frequency histograms were plotted for each time point, blue histograms were plotted for the 0 
hour measurements and red histograms were plotted for the 18 hour time point 
measurements.  Along the X axis is plotted the diameter ranges in µm and along the Y axis is 
plotted the frequency for each range. The number of cells measured for each time point is 
given, colour coded for each histogram. The number of cells measured for each time point 
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was not uniform, thus to normalise the frequency distributions the time point where n was the 
greater was adjusted such that the frequencies plotted were proportional to the time point 
with the lowest n value (e.g. if 0 hr = 300n and 18 hr = 600n then the frequencies for 18 
hours were multiplied by 0.5 to give 18 hr = (600*0.5n). The time point plot normalised for 
figure is indicated by an asterix whose colour corresponds to the appropriate histogram. 
Trend lines were drawn using a moving average function with a period of 2.  
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Figure 4 B – Box and whisker plots to show the range distribution of C. neoformans cell 
diameter – Box and whisker plots were also produced from the same data shown in figure 
4A. The box and whisker plots are arranged in a grid with the corresponding time point and 
condition (e.g. inside J774 macrophages, extracellular in DMEM) horizontally and the strain 
vertically .For each plot the red cross marks the mean and the two blue diamonds mark the 
upper and lower ranges observed. The upper and lower edges of the box represent the upper 
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and lower interquartile ranges of the data and the intersecting line represents the median cell 
diameter.  
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Figure 4C – Bright field images showing Cryptococcus diameter in J774 cells at 0 hour 
and 18 hour time points – J774 macrophages were infected with H99, PLB and PLB2 
Cryptococcus strains. The cells were imaged using a Digital Sight DS-Qi1MC camera 
attached to a Nikon TE2000 microscope. Bright field microscopy was used with a 20 x 
objective lens. Still images were taken every 4 minutes for 20 hours. Still images were 
H99 0 hr H99 18 hr 
  
PLB 0 hr PLB 18 hr 
  
PLB2 0hr PLB2 18hr 
  
C) 
Macrophage 
Cryptococcus 
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captured from the movies, for each strain the same macrophage is represented at 0 hours and 
18 hours.  
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C. neoformans strains H99 (figure 4A-i, figure B H99/0 hr J774 and H99/18 hr J774) and 
PLB2 (figure 4A-iii, figure B PLB2/0 hr J774 and PLB2/18 hr J774) do not show a significant 
growth in cell diameter within infected macrophages over the 18 hour time scale of the 
experiment. PLB however did show a significant increase in diameter during the experiment 
(when α = 0.05, z = -23.88 (< -1.95), P < 0.0001) (figure 4A-ii, figure B PLB/0 hr J774 and 
PLB/18 hr J774) – the mean cell diameter at 0hr was 5.48µm, this increased to 6.77µm at 18 
hours. This suggests that inside infected macrophages a sizeable proportion of PLB cells 
increase in diameter over time whereas H99 and the knockout rescue do not change in size.  
Interestingly there was a significant decrease in the mean cell diameter for H99 (when α = 
0.05, z = 3.86 (> 1.95), P < 0.0001) and PLB2 (when α = 0.05, z = 15.94 (> 1.95), P < 0.0001) 
(figure 4A-i and 4A-iii), this is most likely an indication of active cell proliferation. When C. 
neoformans cells replicate by cell budding smaller daughter cells are produced, thus a 
increasing rate of proliferation overtime will produce a larger population of small cells – 
reducing the mean cell diameter.  
The discovery that PLB knockout produced markedly different cell morphologies to the wild 
type was novel to us. As we had only observed this increase in cell diameter within infected 
macrophages we next wanted to confirm whether it happened to extracellular C. neoformans 
cells.  
In order to assess the morphologies of extracellular C. neoformans we inoculated serum free 
DMEM. Briefly 18B7 opsonised H99, PLB and PLB2 cells were plated into 24 well plates at 
a concentration of 5x10
6 
Cryptococcus in 1ml serum DMEM per well. Again time lapse 
movies were created for each strain over a period of 20 hours. The diameter of approximately 
300 cells per position was measured. One position were measured for each strain per repeat, 
two repeats were measured. 
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We saw a significant decrease in mean cell diameter over the 18 hour time course for H99 
(figure 4A-iv) (when α = 0.05, z = 9.44 (> 1.95), P < 0.0001) and PLB2 (when α = 0.05, z = 
7.81 (> 1.95), P < 0.0001) (figure 4 A-vi). Again we attributed this decrease in mean cell 
diameter to a sign of active cell proliferation. During extracellular growth PLB changed in 
two ways; active proliferation was observed (figure 4 A-v) and there was also a population of 
cells at 18 hours with increased diameters (when α = 0.05, z = 7.37 (> 1.95), P < 0.0001). This 
suggests extracellular PLB both grows in size and proliferates Taken together this data 
suggests that all three C. neoformans strains proliferate better in DMEM than they do inside 
macrophages. Furthermore PLB is the only strain analysed that shows a significant increase in 
cell diameter both within and outside macrophages. PLB cells inside macrophages showed a 
much larger magnitude of expansion than extracellular Cryptococcus. This suggests that the 
conditions which lead to an increase in cell diameter for PLB may be to an extent independent 
of the macrophage; however there seems to be some factor present in the interplay between 
the two cells which exacerbates the morphology. 
3.3 A high throughput lipidomic analysis of C. neoformans  infected macrophages 
Phospholipase B is a lipid modifying enzyme, for this reason we wanted to analysis the 
differences in lipid composition between H99 and PLB infected J774 macrophages. Samples 
from each group were prepared by infecting PMA activated J774 macrophages with H99 and 
PLB. Following infection the cells were incubated for 24 hours before the whole cell lipid 
content of both the macrophages and the infecting Cryptococcus cells were extracted. 
Prepared samples were analysed using FT-ICR mass spectroscopy which provides a very high 
resolution; ideal for lipid analysis where the mass differences between molecules can be very 
small.   
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The normalised m/z data was compared to confirmed lipid m/z values contained within the 
online “Lipids Map Project” (www.lipidmaps.org) database. Two searches were made to 
identify putative lipids using first the Lipids Map glycerophospholipid database search tool 
(http://www.lipidmaps.org/tools/ms/glycerophospholipids_batch.html) and secondly the fatty 
acids database search tool (http://www.lipidmaps.org/tools/ms/fattyacids_batch.html). For 
each search the mass tolerance for a positive identification was set to +/- 0.001 m/z and the 
ion type was set to M-H
-
 (negative ion). 
The phosphoglycerolipid database returned 157 matched masses with a delta value +/- 0.001 
from 6352 normalised m/z data values. Some matched masses corresponded to one or more 
possible lipids with the same mass, as such from 157 matched masses we received 1085 
putative phosphoglycerolipid identities with masses ranging between 353.17396 m/z and 
951.5977 m/z. The fatty acid database search returned 58 matched masses with a delta value 
+/- 0.001 from the 6352 raw m/s data values. From these matched masses 94 putative fatty 
acid identities were given with a mass range between 141.0921m/z and 479.4836 m/z. 
This identity data was matched with the corresponding intensity values from each sample to 
provide an indication of the relative intensities of each putative identity. The mean intensity 
for each sample group (H99 n=3, PLB n=3) was calculated, a student’s T test to calculate the 
significance of the variability between the two sample groups was also calculated. 
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Table 1 – Putative fatty acid lipid identities which are significantly different between 
H99 and PLB – Mass spectrometry m/z data was compared against the ‘Lipid Maps’ fatty 
acid database using the fatty acid database search tool, using a delta value cut off of +/- 
0.001 m/z. Returned lipid identities were correlated to the original intensity data for each 
identified mass. The mean intensity for each sample group – H99 and PLB was calculated for 
the following samples – H99 samples A, B and E – PLB samples A, B and E. A two tailed 
student’s T test was performed to compare the same sample groups. 
 
 
 
 
 
Input mass Matched 
Mass 
(M-H
-
) 
Delta Generic name Abbreviated 
name 
Formula H99 mean 
intensity 
PLB mean 
intensity 
P value 
(H99 vs. 
PLB) 
171.10182 171.1026 0.0008 
oxo-methyl-
octanoic acid 8:0(Ke,Me) C9H15O3 1180.233 212.7229 0.0115 
171.10182 171.1026 0.0008 
hydroxy-nonenoic 
acid 9:1(OH) C9H15O3 1180.233 212.7229 0.0115 
171.10182 171.1026 0.0008 oxo-nonanoic acid 9:0(Ke) C9H15O3 1180.233 212.7229 0.0115 
331.19139 331.1914 0 
epoxy-hydroxy-
eicosapentenoic 
acid 20:5(Ep,OH) C20H27O4 2494.944 3222.471 0.0437 
331.19139 331.1914 0 
oxo-hydroxy-
prostatetraenoic 
acid 
20:4(Ke,OH)-
cyclo C20H27O4 2494.944 3222.471 0.0437 
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Sorting the putative fatty acid identities using the significance of the difference between the 
two samples returned five putative fatty acids (Table 1) whose intensity was significantly 
different (P<0.05)  between the knockout and wild type sample groups. The five fatty acid 
identities returned represent two matched masses – 171.1026 m/z and 331.1914 m/z.  
The three fatty acid identities suggested for the input mass 171.10182 have a matched mass of 
171.1026 (table 1); this works out at as different of 0.0008 from the matched m/z. All three 
putative fatty acids are relatively small chain fatty acids.  The relative intensities between the 
two sample groups (Figure 5 *) suggest that these lipids are more abundant in H99 than they 
are in PLB. 
The two fatty acid identities suggested for the input m/z 331.19139 have a matched mass of 
331.1914 m/z which rounds up to give an exact match to the matched mass (e.g.  delta = 0). 
The two putative fatty acids are both 20 carbon fatty acids. The mean mass intensity for the 
matched m/z is greater in the PLB samples compared to the H99 samples (Figure 5 **) 
suggesting the lipid is found in greater abundance in PLB than it is in H99 (p = 0.0437). The 
two possible lipids are in fact a part of the same metabolic pathway which is derived from the 
essential C18 n-3 fatty acid α-Linolenic acid. The “Lipid map” examples for oxo-hydroxy-
prostatetraenoic acid are PGA3, PGJ3 and PGB3; all of these molecules are prostaglandin like 
derivatives of eicosapentenoic acid. 
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Figure 5 – The intensity of putative fatty acid matched masses between H99 and PLB 
sample groups - Mass spectrometry m/z data was compared against the ‘Lipid Maps’ fatty 
acid database using the fatty acid database search tool, using a delta value cut off of +/- 
0.001 m/z. Returned lipid identities were correlated to the original intensity data for each 
identified mass. The mean intensity for each sample group – H99 and PLB was calculated for 
the following samples – H99 samples A, B and E – PLB samples A, B and E. A two tailed 
student’s T test was performed to compare the same sample groups. Significant matched 
masses (P<0.005) were plotted against mean intensity for H99 and PLB sample groups.         
* Input mass (m/z) 171.10182 (P=0.0115). ** input mass (m/z) 331.19139 (P=0.0437).
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Input mass Matched Mass Delta Head 
group 
Abbreviated name Formula H99 mean 
intensity 
PLB mean intensity P value 
(H99 vs. 
PLB) 
645.45019 645.4501 0.0001 PA PA(12:0/20:1(11Z))  C35H66O8P 46135.24 34317.56 0.014759 
645.45019 645.4501 0.0001 PA PA(10:0/22:1(13Z))  C35H66O8P 46135.24 34317.56 0.014759 
645.45019 645.4501 0.0001 PA PA(16:0/16:1(9Z))  C35H66O8P 46135.24 34317.56 0.014759 
645.45019 645.4501 0.0001 PA PA(15:0/17:1(9Z))  C35H66O8P 46135.24 34317.56 0.014759 
645.45019 645.4501 0.0001 PA PA(14:1(9Z)/18:0)  C35H66O8P 46135.24 34317.56 0.014759 
645.45019 645.4501 0.0001 PA PA(18:0/14:1(9Z))  C35H66O8P 46135.24 34317.56 0.014759 
645.45019 645.4501 0.0001 PA PA(17:1(9Z)/15:0)  C35H66O8P 46135.24 34317.56 0.014759 
645.45019 645.4501 0.0001 PA PA(16:1(9Z)/16:0)  C35H66O8P 46135.24 34317.56 0.014759 
645.45019 645.4501 0.0001 PA PA(22:1(13Z)/10:0)  C35H66O8P 46135.24 34317.56 0.014759 
645.45019 645.4501 0.0001 PA PA(20:1(11Z)/12:0)  C35H66O8P 46135.24 34317.56 0.014759 
645.45019 645.4501 0.0001 PA PA(18:1(9Z)/14:0)  C35H66O8P 46135.24 34317.56 0.014759 
645.45019 645.4501 0.0001 PA PA(14:0/18:1(9Z))  C35H66O8P 46135.24 34317.56 0.014759 
671.46605 671.4657 0.0003 PA PA(14:0/20:2(11Z,14Z)) C37H68O8P 24277.66 19128.41 0.006055 
671.46605 671.4657 0.0003 PA PA(14:1(9Z)/20:1(11Z)) C37H68O8P 24277.66 19128.41 0.006055 
671.46605 671.4657 0.0003 PA PA(12:0/22:2(13Z,16Z))  C37H68O8P 24277.66 19128.41 0.006055 
671.46605 671.4657 0.0003 PA PA(16:0/18:2(9Z,12Z))  C37H68O8P 24277.66 19128.41 0.006055 
671.46605 671.4657 0.0003 PA PA(18:1(9Z)/16:1(9Z))  C37H68O8P 24277.66 19128.41 0.006055 
671.46605 671.4657 0.0003 PA PA(17:2(9Z,12Z)/17:0) C37H68O8P 24277.66 19128.41 0.006055 
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Input mass Matched Mass Delta Head 
group 
Abbreviated name Formula H99 mean 
intensity 
PLB mean intensity P value 
(H99 vs. 
PLB) 
671.46605 671.4657 0.0003 PA PA(18:2(9Z,12Z)/16:0) C37H68O8P 24277.66 19128.41 0.006055 
671.46605 671.4657 0.0003 PA PA(17:1(9Z)/17:1(9Z))  C37H68O8P 24277.66 19128.41 0.006055 
671.46605 671.4657 0.0003 PA PA(17:0/17:2(9Z,12Z))  C37H68O8P 24277.66 19128.41 0.006055 
671.46605 671.4657 0.0003 PA PA(16:1(9Z)/18:1(9Z))  C37H68O8P 24277.66 19128.41 0.006055 
671.46605 671.4657 0.0003 PA PA(22:2(13Z,16Z)/12:0) C37H68O8P 24277.66 19128.41 0.006055 
671.46605 671.4657 0.0003 PA PA(20:2(11Z,14Z)/14:0) C37H68O8P 24277.66 19128.41 0.006055 
671.46605 671.4657 0.0003 PA PA(20:1(11Z)/14:1(9Z)) C37H68O8P 24277.66 19128.41 0.006055 
717.47122 717.4712 0 PG PG(12:0/20:2(11Z,14Z)) C38H70O10P 81404.68 52576.35 0.029281 
717.47122 717.4712 0 PG PG(10:0/22:2(13Z,16Z)) C38H70O10P 81404.68 52576.35 0.029281 
717.47122 717.4712 0 PG PG(14:0/18:2(9Z,12Z))  C38H70O10P 81404.68 52576.35 0.029281 
717.47122 717.4712 0 PG PG(16:1(9Z)/16:1(9Z))  C38H70O10P 81404.68 52576.35 0.029281 
717.47122 717.4712 0 PG PG(18:2(9Z,12Z)/14:0) C38H70O10P 81404.68 52576.35 0.029281 
717.47122 717.4712 0 PG PG(17:2(9Z,12Z)/15:0) C38H70O10P 81404.68 52576.35 0.029281 
717.47122 717.4712 0 PG PG(22:2(13Z,16Z)/10:0) C38H70O10P 81404.68 52576.35 0.029281 
717.47122 717.4712 0 PG PG(20:2(11Z,14Z)/12:0) C38H70O10P 81404.68 52576.35 0.029281 
717.47122 717.4712 0 PG PG(15:0/17:2(9Z,12Z))  C38H70O10P 81404.68 52576.35 0.029281 
743.48714 743.4868 0.0003 PG PG(14:0/20:3(8Z,11Z,14Z))  C40H72O10P 46129.72 28957.4 0.03417 
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Input mass Matched Mass Delta Head 
group 
Abbreviated name Formula H99 mean 
intensity 
PLB mean intensity P value 
(H99 vs. 
PLB) 
743.48714 743.4868 0.0003 PG PG(16:0/18:3(9Z,12Z,15Z))  C40H72O10P 46129.72 28957.4 0.03417 
743.48714 743.4868 0.0003 PG PG(16:1(9Z)/18:2(9Z,12Z))  C40H72O10P 46129.72 28957.4 0.03417 
743.48714 743.4868 0.0003 PG PG(18:3(9Z,12Z,15Z)/16:0) C40H72O10P 46129.72 28957.4 0.03417 
743.48714 743.4868 0.0003 PG PG(17:2(9Z,12Z)/17:1(9Z))  C40H72O10P 46129.72 28957.4 0.03417 
743.48714 743.4868 0.0003 PG PG(17:1(9Z)/17:2(9Z,12Z))  C40H72O10P 46129.72 28957.4 0.03417 
743.48714 743.4868 0.0003 PG PG(20:3(8Z,11Z,14Z)/14:0) C40H72O10P 46129.72 28957.4 0.03417 
743.48714 743.4868 0.0003 PG PG(18:2(9Z,12Z)/16:1(9Z))  C40H72O10P 46129.72 28957.4 0.03417 
879.63422 879.6332 0.001 PI PI(O-18:0/20:0) C47H92O12P 11397.68 2238.575 0.034615 
879.63422 879.6332 0.001 PI PI(O-20:0/18:0) C47H92O12P 11397.68 2238.575 0.034615 
879.63422 879.6332 0.001 PI PI(O-16:0/22:0) C47H92O12P 11397.68 2238.575 0.034615 
937.58129 937.5812 0.0001 PI PI(20:1(11Z)/22:5(7Z,10Z,13Z,16Z,19Z)) C51H86O13P 3065.072 1743.7 0.007674 
937.58129 937.5812 0.0001 PI PI(22:5(7Z,10Z,13Z,16Z,19Z)/20:1(11Z)) C51H86O13P 3065.072 1743.7 0.007674 
937.58129 937.5811 0.0002 PI PI(20:5(5Z,8Z,11Z,14Z,17Z)/22:1(13Z)) C51H86O13P 3065.072 1743.7 0.007674 
937.58129 937.5811 0.0002 PI PI(20:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))  C51H86O13P 3065.072 1743.7 0.007674 
937.58129 937.5811 0.0002 PI PI(22:2(13Z,16Z)/20:4(5Z,8Z,11Z,14Z)) C51H86O13P 3065.072 1743.7 0.007674 
937.58129 937.5811 0.0002 PI PI(22:1(13Z)/20:5(5Z,8Z,11Z,14Z,17Z)) C51H86O13P 3065.072 1743.7 0.007674 
937.58129 937.5811 0.0002 PI PI(20:2(11Z,14Z)/22:4(7Z,10Z,13Z,16Z)) C51H86O13P 3065.072 1743.7 0.007674 
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Input mass Matched Mass Delta Head 
group 
Abbreviated name Formula H99 mean 
intensity 
PLB mean intensity P value 
(H99 vs. 
PLB) 
937.58129 937.5811 0.0002 PI PI(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:0) C51H86O13P 3065.072 1743.7 0.007674 
937.58129 937.5811 0.0002 PI PI(22:4(7Z,10Z,13Z,16Z)/20:2(11Z,14Z)) C51H86O13P 3065.072 1743.7 0.007674 
937.58129 937.5811 0.0002 PI PI(20:4(5Z,8Z,11Z,14Z)/22:2(13Z,16Z)) C51H86O13P 3065.072 1743.7 0.007674 
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Table 2 – Putative phosphoglycerolipid identities which are significantly different 
between H99 and PLB – Mass spectrometry m/z data was compared against the ‘Lipid 
Maps’ phosphoglycerolipid database using the phosphoglycerolipid database search tool, 
with a delta value cut off of +/- 0.001 m/z. Returned lipid identities were correlated to the 
original intensity data for each identified mass. The mean intensity for each sample group – 
H99 and PLB was calculated for the following samples – H99 samples A, B and E – PLB 
samples A, B and E. A two tailed student’s T test was performed to compare the same sample 
groups. 
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Sorting the phosphogycerolipids by significance in the same way as the fatty acids revealed 
55 putative glycerophospholipids which were significantly different between sample groups. 
The 55 returned lipids represent 6 input m/z values which had matched m/z with delta values 
between 0 and 0.0003 (Table 2). The matched m/z values were 645.4501 m/z, 671.4657 m/z, 
717.4712 m/z, 879.6332 m/z and 937.5811 m/z. Interestingly all the mean intensities for each 
matched mass were greater in the H99 sample group than they were in the PLB sample group 
(Figure 6). The 55 putative phosphoglycerolipids identified fell into three different 
phosphoglycerolipid groups, the three groups were as follows: glycerophosphates (PA), 
glycerophosphoglycerols (PG) and glycerophosphoinisitols (PI). 
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Figure 6 – The intensity of putative phosphoglycerolipids matched masses between H99 
and PLB sample groups - Mass spectrometry m/z data was compared against the ‘Lipid 
Maps’ phosphoglycerolipid database using the phosphoglycerolipid database search tool, 
using a delta value cut off of +/- 0.001 m/z. Returned lipid identities were correlated to the 
original intensity data for each identified mass. The mean intensity for each sample group – 
H99 and PLB was calculated for the following samples – H99 samples A, B and E – PLB 
samples A, B and E. A two tailed student’s T test was performed to compare the same sample 
groups. Significant matched masses (P<0.005) were plotted against mean intensity for H99 
and PLB sample groups.  * Input mass (m/z) 645.4501 (P=0.014759). ** Input mass (m/z) 
671.46605 (P=0.006055). *** Input mass (m/z) 717.47122 (P=0.29281). **** Input mass 
(m/z) 743.48714 (P=0.3417). ***** Input mass (m/z) 879.634.22 (P=0.034615). ****** 
Input mass (m/z) 937.58129 (P=0.007674)  
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3.4 Cryptococcal intracellular proliferation can be modulated with eicosanoid 
modifying treatments  
Having discovered phenotypic and morphological differences between the PLB1 gene 
knockout mutant PLB and the wild type C. neoformans strain H99 we next wanted to see 
whether we could begin elucidate some of the possible biological mechanisms that Plb is a 
part of during infection. One current theory for the importance of Plb during C. neoformans 
infection of macrophages is that the phospholipase produces a reservoir of arachidonic acid 
which would allow the production of various bioactive eicosanoids. As well as producing 
evidence for a putative eicosanoid and arachidonic acid like lipid structures using mass 
spectrometry in this study it has also been observed in other studies that eicosanoids are 
produced by C. neoformans cells in liquid culture. In addition to this is well established that 
eicosanoids such as prostaglandins have bioactive roles within macrophages which contribute 
to the generation of an immune response. Thus it is not such a leap to theorise that the loss of 
eicosanoid production due to PLB1 knockout could contribute to some of the differences 
observed differences between PLB and wild type H99. 
To test this theory we decided to see if we could recreate the phenotype observed for PLB in 
H99 by applying a treatment which is known to modulate eicosanoid metabolism. The 
treatment we used is a combination of two drugs – bezafibrate (BEZ) and 
medroxyprogesterone acetate (MPA) which together will be referred to as BAP. We chose 
this drug combination because they have been reported to alter eicosanoid metabolism within 
cells (Khanim et al., 2009). We hoped this combination of compounds could help confirm if 
eicosanoid metabolism contributes to Cryptococcus virulence.  
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Figure 7 – IPR assay comparing the intracellular proliferation of H99 and PLB with and 
without BAP treatment – H99 and PLB infected macrophages were either left untreated 
(H99n, PLBn) or were treated with bezafibrate and medroxyprogesterone. Briefly 1x10
6
 un 
opsonised C. neoformans strain was added to 1x10
5
 PMA activated J774 macrophages plated 
in 24 well tissue culture plates in 1ml serum free DMEM supplemented with bezafibrate 
(stock 0.05 M) and medroxyprogesterone (stock 0.5 mM) at a working concentration of 1 in 
1000. After two hours (0 hours) extracellular Cryptococcus cells were washed away, the 
number of intracellular Cryptococcus were counted at 0, 18 and 24 hour time points, the 18 
hour and 24 hour time point wells were re supplemented with the same BAP dosage following 
washing. The IPR was calculated from the maximum intracellular cell number divided by the 
initial uptake at 0 hour. After two hours (0 hours) extracellular Cryptococcus cells were 
washed away, the number of intracellular Cryptococcus were counted at 0, 18 and 24 hour 
time points. The IPR was calculated from the maximum intracellular cell number divided by 
the initial uptake at 0 hour. Filled in bars represent the mean IPR value for each strain (n=3), 
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error bars represent 2x standard error. A two tailed Student’s t test was performed for the 
following groups: H99n vs. H99t (* P = 0.03) and PLBn vs. PLBt (**P= 0.64).  
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When J774 macrophages were treated with BAP at the same time as H99 infection (Figure 5 -
H99 t) there was roughly a 50% decrease in intracellular proliferation compared to H99 in 
untreated J774 cells (Figure 7 – H99n). Interestingly BAP treatment brought the intracellular 
proliferation rate of H99 down to the same level untreated PLB (Figure 7 – PLBn). BAP 
treatment of J774 macrophages infected with PLB (Figure 7 – PLBn) did not significantly 
affect the intracellular proliferation of PLBt compared to non treatment (Figure 7 – PLBt), 
however the intracellular proliferation of PLBn was already reduced compared to H99. Taken 
together this data suggests that the intracellular proliferation rate of the H99 wild type can be 
brought down to the level of the PLB1 knockout PLB using BAP which is an eicosanoid 
altering treatment. 
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DISCUSSION 
Our investigation has described previously unreported phenotypic and morphological 
observations for the PLB1 knockout strain PLB which were not observed in the wild type 
parent strain H99 or in the PLB1 rescue strains PLB1 and PLB2. 
PLB proliferative deficiency 
Our finding that PLB appears to grow badly in J774 macrophages compared to H99, PLB1 
and PLB2 (Figure 1) indicates that Plb is important for intracellular survival within 
macrophages. A role for Plb in intracellular survival is supported by previous studies which 
report a correlation between Plb expression in C. neoformans and a greater number fungal 
burden in the lungs of mice following nasal infection (Chayakulkeeree et al., 2011). Plb could 
contribute to increased cryptococcal burden inside macrophages possibly by encouraging 
proliferation and also by providing protection against microbial killing which otherwise 
would reduce intracellular numbers. Support for Plb’s role in proliferation is provided by a 
study using the same PLB1 knockout strain as us which reported that PLB had a significantly 
slower budding rate inside a macrophage cell line than H99, PLB1 or PLB2 (Cox et al., 
2001).  
Although the molecular basis for PLB’s growth deficiency cannot be defined from our data 
we have seen that the deficiency is not dependant on the cryptococcal burden within 
macrophages (Figure 3A), or the activation state of macrophages (Figure 2). Further work 
must be done to characterise PLB’s growth within macrophages. This work will include IPR 
assays within primary human macrophages to ensure that the phenotype observed is not an 
artefact of our experimental model. Work must also be performed to determine whether the 
growth deficiency is intrinsic to the Cryptococcus or whether something is being produced by 
the macrophage to halt proliferation. 
Robert Evans 
55 
 
Cell size 
The presence of C. neoformans cells which are above average in diameter have been reported 
in vitro as well as in vivo, these large cells are often referred to as ‘Titan cells’ in the 
literature. The largest PLB cell we measured was 14.56 µm in diameter which is about 2 times 
bigger than a normal cell (Figure 4B – PLB/18 hr J774). In terms of Titan Cell morphologies 
previously described this is within the size range for a titan cell but is at the lower end of the 
size scale. Normal Cryptococcus cells grow to be between 5 and 10 µm in diameter, whereas 
Titan Cells are generally considered to be above 10 µm in diameter, and can grow up to 100 
µm in diameter (10 times the normal size) (Okagaki et al., 2010). Although our cells are small 
compared to some studies it is likely that they were still growing when we measured them at 
18 hours and thus if we’d let the experiment run for longer we may have measured even larger 
cells. It is also possible that our tissue culture model constrained the growth of PLB. 
Our measurements only measured the diameter of the cell body and not the diameter of the 
polysaccharide capsule, as this is hard to measure inside macrophages without specific 
staining. With the capsule diameter included our cells could in fact be much larger than we 
have reported. To analyse the absolute diameter of our cells we would have to collect 
intracellular Cryptococcus cells from within J774 cells using a cell lysis step similar to that 
used in the IPR. C. neoformans cells within the cell lysate would then have to be stained to 
visualise their polysaccharide capsule using a capsule binding monoclonal antibody and an 
appropriate fluorophore.  
Interestingly we observed that inside macrophages PLB grew in size but did not proliferate 
(Figure 4A). This could provide an explanation for PLB’s growth deficiency which was 
observed in our first experiment (Figure 1); it seems that instead of proliferating like wild 
type cells PLB cells instead divert their efforts to growing larger.  
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The reason why only the PLB1 knockout strain grew larger is unclear but it suggests that 
deficiency in Plb may be responsible for this morphology. The formation of Titan Cells has 
been linked to extracellular signalling between Cryptococcus cells which are interpreted by G 
protein receptors on the cell surface (Okagaki et al., 2011). The fact that only the PLB1 
knockout strain and not the knockout grows in size could indicate that something in the 
normal signalling pathway is being perturbed by Plb deficiency. Plb knockout strains of C. 
neoformans have previously been reported to have abnormal membrane structure (Siafakas et 
al., 2007). Plb is a phospholipid modifying enzyme so knockout could affect the lipid 
composition of a cellular membrane and as a result the function of membrane signalling 
proteins within it.  
We report that PLB increases in diameter both inside J774 macrophages and extracellulary in 
DMEM (Figure 4A). Although PLB cells did increase in size in the negative control the 
maximum cell diameter did not exceed the 10 µm diameter requirement for Titan Cell 
morphology. Thus Titan Cell morphology is only seen when PLB is inside J774 macrophages. 
This leads us to conclude that there must be something which is either present within the 
macrophage or produced by C. neoformans in response to being inside a macrophage which 
triggers the Titan Cell response. Extracellular Titan Cell formation can be stimulated in vitro 
by reusing medium that has previously been used to grow macrophages (Okagaki et al., 
2010), this suggests that there is a molecule produced by macrophages which stimulates Titan 
Cell development. When this data is taken into consideration with our own data showing that 
only intracellular cells grow larger this suggests that the development of the observed 
morphology is due to an interaction between Cryptococcus and macrophages. 
The Titan Cells morphology is thought to protect C. neoformans by increasing the resistance 
to phagocytosis and also protecting Cryptococcus cells from microbial killing mechanism 
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within the macrophage. Although Titan Cell can protect C. neoformans the morphology in 
fact reduces virulence, this is thought to be because Titan Cells do not appear to disseminate 
to the brain (Okagaki et al., 2010). A similar inability to disseminate from the lungs has also 
been reported for a Plb deficient Cryptococcus strain (Santangelo et al., 2004), this study 
found that Plb was required for dissemination from the lungs into the blood in mice but was 
not required for dissemination from the blood into the brain following intravenous 
inoculation. Although this study did not report any change in C. neoformans morphology it is 
possible that Titan Cell morphology in the Plb deficient mutant could be an explanation for 
these results. In addition to this we have previously reported that the PLB mutant has a 
reduced rate of macrophage escape compared to H99 which could be a compounding factor in 
reducing dissemination (Chayakulkeeree et al., 2011). 
Although PLB produces larger cells we cannot be certain that they are the same as previously 
described in vivo Titan Cells. Thus further work must be performed to firstly define what 
biochemical factors make Titan cells different from normal Cryptococcus cells apart from 
their size; this could include gene expression analysis as well as lipidomic mass spectrometry 
to compare the genes and lipids involved in creating a Titan Cell like state. Further work must 
be done to confirm that PLB cells grow larger with primary human macrophages, we could 
also analyse cell size in a suitable animal model; this will also allow us to examine 
dissemination to the central nervous system. 
Lipidomic study 
To our knowledge we have performed the first whole cell lipidomic study to analyse C. 
neoformans infected macrophages with infecting Cryptococcus cells in situ. Refinement of 
this technique in the future will allow us to better examine the host pathogen interaction 
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between the macrophage and Cryptococcus and give us a snapshot of lipid metabolism during 
fungal infection.  
Analysis of the data set generated by the mass spectrometry analysis identified 1143 putative 
fatty acid and glycerophospholipid identities. Of these 1143 identities 61 were identified as 
being significantly higher in intensity for either H99 or PLB sample groups (Table 1 and table 
2) (The intensity measure although not fully quantitative gives a good indication of the 
abundance of a lipid in a given sample). PCA analysis of the differences between strains 
suggest that knockout of Plb did not cause any large scale changes in the lipid composition of 
the cells (data unpublished). This suggests that perhaps only a few lipids are dependent on 
Plb’s expression; it could also mean that there is a certain level of redundancy – this is 
understandable as macrophages themselves express phospholipase enzymes when activated 
(Adams and Hamilton, 1984). 
As a preliminary study we feel that the data we have provided proves the concept that 
differences in lipid composition between macrophages infected with different Cryptococcus 
strains can be compared using mass spectrometry. The main criticism of our study is that it 
was not really large enough to be conclusive. In future studies we must expand to include 
more experimental repeats to ensure that any differences we find are due to biological 
differences and not experimental error and experimental noise. We also hope that with a 
greater number of repeats we will be able to identify an even greater number of differences 
between strain sample groups. In the future we must also expand the study to compare more 
Cryptococcus strains such as the PLB1 rescues PLB1 and PLB2. These two strains are 
required so that we can more confidently assert that differences between H99 and PLB 
observed are due to the knockout of the PLB1 gene. We must also expand the study to include 
control samples. Desirable controls include uninfected macrophages as well as extracellular 
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C. neoformans. These extracellular Cryptococcus controls would be in the form of 
Cryptococcus cells which have been collected following macrophage infection. These two 
controls would allow us to begin to determine whether a lipid we have identified is of 
macrophage or cryptococcal origin. It may also be possible to differentiate between 
Cryptococcus and macrophage lipids by growing our C. neoformans overnight cultures in 
medium in which normal glucose has been substituted for a C
14
 labelled glucose. Growing 
Cryptococcus on this different carbon isotope will allow us to differentiate between lipids of 
different cellular origin following mass spectrometry analysis; this is because the same lipid 
molecule from either macrophages or C. neoformans cells would have a different but 
identifiable mass.  
Another shortcoming of our lipidomic study is that although we have identified over 1000 
putative lipids we cannot definitively confirm a lipid’s identity from a m/z match. The reason 
for this is that there are sometimes multiple lipid molecules for a certain m/z which have the 
same molecular mass but a different structural configuration. For this reason in future studies 
we must perform tandem MS/MS analysis. This technique makes use of two mass 
spectrometers which work in concert with one another. The sample is ionised in the first mass 
spectrometer to create a mass spectra, ions of interest from this first mass spectrometer are 
isolated and sent to the second mass spectrometer where fragmentation analysis occurs. Every 
molecule has a different fragmentation signature, thus using fragmentation analysis one can 
tell the difference between two molecules even if they have the same molecular mass using 
their structure. By comparing the fragmentation patterns we observe using MS/MS to an 
online database such as ‘Lipid Maps’ we will be able to more definitively confirm lipid 
identities. 
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Without knowing the correct identities of the significant lipids we have identified not much 
can be concluded about their biological significance. We observed that all the significantly 
different putative glycerophospholipids appeared to have a higher abundance in H99 than they 
did in PLB. This could be a coincidence. However it may be that the glycerophospholipid 
lipids measured are a part of the same metabolic pathway, and as such an increase in the 
uppermost metabolite could lead to a general increase throughout the pathway. Of the putative 
fatty acids significantly different between the two sample groups (Table 1) we found a group 
of short chained 8-9 carbon chain fatty acids and two 20 carbon chain fatty acids. The short 
chain fatty acids we detected are derivatives of octanoic, nonenoic and nonanoic acid; each 
had the same matched m/z of 171.10182. These fatty acids appeared to be more abundant in 
H99 than they were in PLB. The two 20 carbon chain fatty acids we detected - epoxy-
hydroxy-eicosapentenoic acid and oxo-hydroxy-prostatetraenoic acid are interesting as they 
are metabolites of α-Linolenic acid, metabolites of this pathway are bioactive molecules 
which are thought to have opposite effects to prostaglandins in that they are anti 
inflammatory, thus increased levels of these lipids in PLB may negatively affect wild type 
virulence by inhibiting eicosanoid production (Singer et al., 2008). 
BAP combination treatment 
We have found that a combination treatment of BEZ and MPA appears to slow or even inhibit 
the growth of wild type H99 Cryptococcus inside infected J774 macrophages (Figure 7). 
BEZ and MPA (BAP) are two existing drugs which have been shown to have bioactive 
effects on the expression of prostaglandins in mammalian cells. Both drugs are commercially 
available and off patent; BEZ is an anti-cholesterol drug whereas MPA is a female 
contraceptive treatment.  BAP combination treatment is currently being pioneered as an 
efficacious treatment for acute myeloid leukaemia (AML). The anti neoplasic effects of these 
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two drugs is reported to be due to their combined ability to increase the levels of 
prostaglandin D2 (PGD2) in cancer cells via an increase in synthesis and a decrease in 
metabolism. Increased levels of PGD2 inside cells leads to a direct increase in PGD2’s de-
hydrated form called 15 deoxyΔ12, 14 prostaglandin J2 (15d-PGJ2) (Khanim et al., 2009). It was 
due to these eicosanoid modifying effects that we chose to test BAP treatment on                   
C. neoformans infected J774 macrophages in order to expand the theory that Plb’s 
contribution to virulence might be because of its ability to influence eicosanoid production 
within the macrophage. 15d-PGJ2 is different to most prostaglandins because it does not have 
a specific extracellular receptor, however it does have an intracellular receptor called PPARγ. 
This receptor is thought to be the main signalling component which mediates 15d-PGJ2’s 
bioactivity within cells (Scher and Pillinger, 2005).  
We do not know whether infected J774 macrophages treated with BAP produce increased 
levels of 15d-PGJ2 so we cannot say for certain that 15d-PGJ2 is responsible for the decrease 
in intracellular proliferation observed. If in fact if BAP is acting via 15d-PGJ2 an exact 
molecular mechanism would still be hard to deduce; like most eicosanoids 15d-PGJ2 is 
complicated and contradictory in nature. In macrophages PPARγ ligation via 15d-PGJ2 
generally produces an anti inflammatory response which is characterised by inhibition of 
inflammatory cytokines (Jiang et al., 1998), decreased macrophage activation and decreased 
production of inducible nitric oxide synthase (iNOS) (Ricote et al., 1998). However 15d-PGJ2 
also has pro inflammatory properties (Tontonoz et al., 1998). The diversity of function is 
probably due to among other things the magnitude of PPARγ activation, the subtype of 
macrophage and the macrophage’s current anatomical location (Scher and Pillinger, 2005) . 
To properly elucidate the pharmaceutical effects that BAP has on Cryptococcus infected 
macrophages we must find out what happens when BAP treatment is applied. This will 
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include analysis of gene expression with and without BAP treatment to observe the 
transcriptional changes the drug may exert. In addition to this we could examine the activation 
phenotype of macrophages following treatment, for example we could measure prostaglandin 
and cytokine secretion as well as cell surface molecule expression on macrophages.  
The anti-tumour effects of 15d-PGJ2 are mainly linked to its ability to induce apoptosis in 
tumour cells (Date et al., 2003, Khanim et al., 2009). Increased apoptosis is a desirable effect 
when combating tumours however one of the short comings of the IPR assay is that a drop in 
intracellular proliferation could be mimicked by increased macrophage cell death; this is 
because only Cryptococcus cells within live macrophages are counted. This potential false 
positive reading is a viable explanation for our observations as the J774 macrophages we used 
in our study is an immortalised tumour derived cell line and as such 15d-PGJ2 might have 
similar apoptotic effects as it does for other tumour cells. To compound the issue 15d-PGJ2 
has also been reported to cause apoptosis in non neoplasic human macrophages (Chinetti et 
al., 1998). The question over whether BAP causes apoptosis of macrophages instead of 
affecting Cryptococcus proliferation could be easily answered using an apoptosis assay to 
quantify the level of apoptosis over time in BAP treated and untreated J774 macrophages.  
Even if BAP combination treatment does reduce the proliferation Cryptococcus we still 
cannot state for certain that this is due to specific pharmacological effects of the drug 
treatment. In addition to the two drug compounds we also in advertently treated the 
macrophages with DMSO and ethanol which were the solvents for the two drugs. It is 
possible that these two compounds may have affected either the health of either the 
macrophages or the Cryptococcus cells – this could be via the apoptosis false positive 
mechanism previously discussed or by signalling in some way to the cells. To remove this 
potential false positive result we must perform a vehicle control where we compare the 
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intracellular proliferation of BAP treated macrophages with macrophages treated with DMSO 
and ethanol only. Further work could also be done to find the minimum effective dose needed 
to produce a significant decrease in proliferation.  
If BAP treatment does in fact inhibit the intracellular growth of Cryptococcus then it may be 
possible to develop the drug combination as a treatment for cryptococcosis. The current 
treatment for cryptococcosis makes use of the anti fungal drug Fluconazole. A relatively poor 
prognosis for cryptococcosis even with treatment means there is a demand for effective 
compounds which could be given alongside Fluconazole to improve treatment. Development 
of BAP as a supplementary treatment to antifungal drugs would first require in vitro IPR 
experiments comparing the effectiveness of Fluconazole at halting fungal growth with and 
without additional BAP; it may also be useful to test each BAP drug (BEZ and MPA) on their 
own to see if both drugs are required or if one or the other is sufficient. Once solid evidence 
of in vitro treatment using BAP alongside Fluconazole is produced we could then move to an 
in vivo model of cryptococcosis using an animal model such as mice. If the drug remains 
effective and safe in animal models it may be possible to proceed to small scale human trials 
to test efficacy and safety. 
Conclusion 
As a result of this study we have reported both phenotypic and morphological differences 
which appear to correlate to the knockout of phospholipase B expression in C. neoformans. 
These observations point to the conclusion that phospholipase B expression is important for 
the normal function of Cryptococcus cells within murine macrophages. In the future we must 
expand upon and explore fully the molecular mechanisms behind these novel observations. In 
doing so we will gain a greater understanding of how phospholipase B and lipid signalling 
contribute to virulence. This knowledge should help ourselves and others in the mycology 
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field to better understand the generation of anti fungal immune responses; it will also help us 
design better treatments for cryptococcosis to improve the prognosis of disease sufferers 
around the world.  
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PART TWO 
An investigation into the properties of two Bdellovibrio 
bacteriovorus C-di-GMP metabolism proteins – Bd2325 
and Bd1971 
Supervisor – Dr Andrew Lovering 
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INTRODUCTION 
1.1 Bdellovibrio bacteriovorus 
Bdellovibrio bacteriovorus is a small motile bacterium which has evolved to predate gram 
negative bacteria. Following initial attachment to the prey cell, B. bacteriovorus burrows 
through the cell wall into the periplasmic space where it modifies the prey cell to create an 
ideal environment for replication. Although B. bacteriovorus was appreciated around the time 
of its discovery for its unique and interesting lifecycle, the full potential of the bacteria has 
only recently been realised thanks to modern molecular biology techniques. The resurgence of 
interest surrounding B. bacteriovorus can be ascribed partly to its potential use as a ‘living 
antibiotic’, and partly to a growing appreciation of the molecular mechanisms regulating its 
lifecycle; knockout of these mechanisms often cause distinct observable mutant phenotypes 
and, because many of the same regulatory pathways in B. Bacteriovorus can be found across 
the bacterial kingdom they represent an exciting microbiological research tool (Sockett, 
2009). 
Strains of B. bacteriovorus have been isolated from a variety of different natural habits such 
as sewage, freshwater (Fry and Staples, 1976), soil (Klein and Casida, 1967) and the guts of 
animals such as humans (Schwudke et al., 2001). The variety of habitats B. bacteriovorus 
grows in is testament to the wide range of prey cells which B. bacteriovorus predates; as each 
habitat must provide at least one prey species in order for the predator to grow and divide. 
Predation by B. bacteriovorus is confined to gram negative species of bacteria, however 
within this group a diverse selection of prey species has been identified including important 
human pathogenic genera e.g. Escherichia, Enterobacter, Vibrio, Shigella, Salmonella and 
Yersinia to name a few (Dashiff et al., 2011). The potent and wide reaching bactericidal 
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ability that B. bacteriovorus displays has lead some researchers to speculate that a new 
generation of ‘living antibiotics’ could be produced using modified B. bacteriovorus strains 
applied directly to infected tissue (Dwidar et al., 2012). 
B. bacteriovorus cells are usually found in a predatory ‘attack phase’, however a host 
independent (HI) or anexic phase can also be occasionally observed (Sockett, 2009). The cells 
displaying this HI phenotype are naturally occurring mutants of wild type B. bacteriovorus 
strains. HI cells are capable of forming biofilms in nutrient rich conditions, and disperse back 
into independent attack phase cells upon the addition of  prey cells - in this case E. coli 
(Medina and Kadouri, 2009).The reversible sedentary HI phenotype is assumed to be a 
mechanism which has evolved to ensure the survival of B. bacteriovorus even when prey cells 
are scarce.  
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1.2 – Bdellovibrio bacteriovorus lifecycle 
 
 
 
Figure 1:  Diagrammatical representation of the B. bacteriovorus predatory lifecycle – 
A) Small, highly motile flagellated attack phase B. bacteriovorus cells hunt for prey via 
chemotaxic mechanisms. B) Rod shaped gram negative prey cell - the blue outer ring 
represents the periplasm and the white inner circle represents the cytoplasm. C) An attack 
phase B. bacteriovorus cell locates a prey cell, initial reversible interactions form between 
the two cells as they contact. These contacts grow stronger with time until they become 
irreversible. D) The B. bacteriovorus cell burrows through the cell wall of the prey cell into 
the periplasm. E) B. bacteriovorus modifies the prey cell using hydrolytic enzymes to create 
the bdelloplast. These enzymes modify the prey cell wall and membrane and also digest parts 
A. 
G. 
F. 
E. 
D. 
C. 
H. 
B. 
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of the cell as a food source. During bdelloplast formation the rod shape of the prey cell 
changes to a sphere. F) B. bacteriovorus elongates within the periplasm until it forms a long 
filament the circumference of the bdelloplast. G) During cell division, the long filamented 
mother cell body septates to produce multiple progeny. H) The new progeny grow flagella, 
lyse the bdelloplast and then swim away to form new attack phase cells - all that is left of the 
prey cell is a dead husk.  
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Motility and hunting 
Motility is very important for B. bacteriovorus’s predatory life style because the bacterium 
must search for prey cells to predate before growth and cell division can take place. The major 
contributor to B. bacteriovorus motility is a single sheathed flagellum (Thomashow and 
Rittenberg, 1985). Using this flagella B. bacteriovorus can reach very high speeds of up to 
160 µm s
− 1
 in liquid culture (Lambert et al., 2006). In addition to flagellar motility B. 
bacteriovorus can also move along solid surfaces using gliding motility; albeit at markedly 
lower speeds (Lambert et al., 2011). 
Studies to discover how B. Bacteriovorus locates its prey during the hunt have discovered that 
attack phase cells are chemotatic towards high concentrations of bacteria (Straley and Conti, 
1977). Bacterial products produced by prey cells such as amino acids may also possible 
chemotactic signals (LaMarre et al., 1977). Molecular studies indicate that chemotaxis 
proteins in B. bacteriovorus such as methyl accepting chemotactic protein (MCP) encoded by 
the gene mcp2 may play a role in the hunting of prey (Lambert et al., 2003). Chemotaxis 
towards high concentrations of bacteria could explain the observed predation of biofilms by 
B. bacteriovorus (Núñez et al., 2005).   
Attachment and invasion 
Once a B. bacteriovorus attack phase cell has located its prey the intracellular phase of the 
predatory cycle begins. The first stage of the intracellular phase involves the formation of 
strong physical attachments to the prey cell surface. It was initially thought that B. 
bacteriovorus made use of its high speed to forcibly ram itself into prey in order to physically 
attach to the cell wall (Sockett, 2009), however experiments using flagellin subunit (fliC1-6) 
attack phase knockout mutants lacking the motility of the wild type found this not to be the 
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case. These mutants were less efficient at killing prey due to an inability to seek out prey 
however when they were applied directly to prey cells predation was unaffected (Lambert et 
al., 2011). It is now thought that host cell recognition and initial attachment it is mediated by 
much more specific membrane interactions. 
Although the exact nature of the interactions is only starting to be understood, it is known that 
initial contact with the prey cell is reversible and transient - lasting only a couple of minutes 
(Lambert et al., 2006). After this initial period however the attachments significantly 
strengthen and B. bacteriovorus becomes committed to the predatory cycle (Burnham et al., 
1968). Candidate molecules for these attachments include Type IV pili. Type IV pili are fibre 
like structures a few microns in length which extend out from the cell wall of some bacteria. 
Type IV pili are found throughout the bacterial kingdom and have multiple functions 
including attachment to other cells, motility and disease pathogenesis (Craig et al., 2004). 
Type IV pili can be found expressed on the surface of around 30% of attack phase B. 
bacteriovorus cells at the opposite end of the cell to the flagellum (Evans et al., 2007). The 
importance of Type IV pili to the predatory lifecycle of B. bacteriovorus has been illustrated 
via mutation of the gene PilA which encodes PilA – the major structural component of Type 
IV pili fibres. Mutant strains lacking a functional PilA gene cannot assemble Type IV pili on 
the cell surface and are deficient in predation even when applied directly onto the surface of 
prey cells (Evans et al., 2007).             
Once attached to the surface of a prey cell B. bacteriovorus creates a small pore within the 
prey cell wall allowing it to gain entry into the periplasm. The events which create this pore 
are not fully understood but it is thought that B. bacteriovorus might use some of the digestive 
enzymes which it possesses to weaken structural components of the prey cell wall such as 
peptidoglycan cross linking (Lambert et al., 2006). The pore, once it is created is not much 
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larger than B. bacteriovorus itself. To enter into the periplasm the predator cell pulls itself 
through the pore; the pulling force required for this may be generated by the contraction of the 
Type IV pili previously mentioned. Following entry into the periplasm the site of entry is 
sealed and B. bacteriovorus initiates the next major stage of its lifecycle; the remodelling of 
the prey cell into the Bdelloplast (Sockett, 2009, Lambert et al., 2006). 
Modification and replication 
The bdelloplast is the name given to the structure formed by the modification of a prey cell by 
the invading predator cell. There are thought to be a number of reasons for the formation of 
the bdelloplast, the first and foremost being the creation of a safe niche in which B. 
bacteriovorus is able to grow and reproduce. During the bdelloplast phase, catabolism of prey 
cell constituents creates readily available nutrients for cell growth and adjustment of the prey 
cell’s structural integrity occurs which prevents prey cell lysis from osmotic stress (Lambert 
et al., 2006). The second reason for the bdelloplast may be in order to produce an occupancy 
signal which is recognisable to other attack phase B. bacteriovorus cells (Lerner et al., 2012). 
This signal is important because a second bacterium attempting to enter an already occupied 
cell could cause the death of both B. bacteriovorus cells. 
Modification of the host cell into the bdelloplast occurs via the action of hydrolytic enzymes 
which are produced by B. bacteriovorus upon entry into the periplasm. Some of these 
enzymes can break apart prey cell wall peptidoglycan cross linking (Thomashow and 
Rittenberg, 1978b). An effect of this modification seems to be the unification of the periplasm 
and the prey cell cytoplasm (Cover et al., 1984); this has the effect of allowing small 
molecules to pass freely between the two spaces, allowing B. bacteriovorus access to nutrients 
usually confined to prey cell cytoplasm. Modification of peptidoglycan cross linking also 
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increases the tolerance of the prey cell wall to osmotic stresses which may occur during 
replication, preventing premature bdelloplast lysis (Lambert et al., 2006).  
During bdelloplast formation, a change in prey cell shape occurs turning the cell from a rod 
shaped morphology to a spherical morphology - N.B. this is assuming that prey cell is a rod 
shaped bacteria; the standard prey model in B. bacteriovorus research is the rod shaped 
bacteria Escherichia coli, thus most of what is known about prey cell interaction is based on 
rod shaped prey cells. This morphological change firstly increases the volume of the 
bdelloplast, allowing for increased predator cell growth during replication but in addition it 
seems to form the cellular occupancy signal that invading B. bacteriovorus cells use to stop 
other attack phase cells entering their prey cell. A recent study identified two B. bacteriovorus 
genes which were responsible for this morphological change – Bd0816 and Bd3459. These 
genes code for two peptidoglycan modifying proteins which belong to the ‘class C penicillin 
binding protein’ (PBP) family; class C PBP proteins remodel peptidoglycan by hydrolysing 
peptidoglycan crosslinking. The two genes were found to be up regulated during and directly 
after prey cell invasion. Knockout of the two genes produced B. bacteriovorus mutants which 
took longer to invade prey cells and produced bdelloplasts which remained rod shaped. 
Importantly these rod shaped bdelloplasts were found to be less efficient at producing an 
occupancy signal as illustrated by a higher frequency of double occupancy - characterised by 
a second B. bacteriovorus entering the bdelloplast (Lerner et al., 2012).   
An ever present issue during formation of the bdelloplast is the balance which must be stuck 
between breaking down prey cell barriers which hinder the growth of B. bacteriovorus and 
irreparably destabilising the structure of the prey cell - which itself could cause premature 
bdelloplast lysis. In this respect studies have revealed a B. bacteriovorus regulatory system 
which selectively modifies prey cell wall peptidoglycan via N-deacetylation, protecting it 
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against cleavage by B. bacteriovorus hydrolase enzymes (Thomashow and Rittenberg, 
1978a). Using this mechanism B. bacteriovorus may be able to control the levels of 
hydrolysis once the bdelloplast is formed, thus preserving the environment it has created.   
It is inside the periplasm of the Bdelloplast that B. bacteriovorus replication takes place. The 
first stage of B. bacteriovorus replication involves the elongation of the parent cell until it has 
formed a long filament spanning the entire circumference of the Bdelloplast. Replication of B. 
bacteriovorus, like replication of any cell, requires the expenditure of significant amounts of 
energy as new genomes and organelles are produced. All of the energy and nutrients needed 
for B. bacteriovorus replication are obtained from digestion of the prey cell. This mode of 
replication produces logistical challenges for B. bacteriovorus, for instance the size of the B. 
bacteriovorus genome is comparable with that of the prey cell – thus the replication of 
multiple genomes from a single prey cell requires de novo synthesis of nearly all the 
nucleotides needed. To accomplish this task B. bacteriovorus has evolved an array of 
digestive enzymes to break down prey cell biological macromolecules as well as complex 
purine and pyrimidine synthesis systems (Lambert et al., 2006) .  
Once B. bacteriovorus has elongated it begins to septate at multiple points along the filament 
to form usually four progeny cells (Lambert et al., 2006). Following septation, each progeny 
cell grows a new flagellum. Finally once the progeny are ready to leave, the bdelloplast is 
lysed and the new cells burst out to form the next wave of attack phase cells and the predatory 
cycle beings anew. 
1.3 Bdellovibrio bacteriovorus and C-di-GMP signalling 
The entire predatory process from initial attachment to bdelloplast lysis takes approximately 
3.5 hours (Lambert et al., 2006), each step within the cycle must be dynamically controlled to 
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ensure the proper progression and timing of events. The molecular basis of these B. 
bacteriovorus control mechanisms are only just being elucidated, one important cellular 
regulator appears to be the small secondary messenger molecule Bis-(3’-5’)-cyclic dimeric 
guanosine monophosphate (C-di-GMP) (Hobley et al., 2012). The importance of C-di-GMP 
in the control of cellular processes is not just confined to B. bacteriovorus - in fact it is 
becoming increasing clear that C-di-GMP is a key secondary messenger across the bacterial 
kingdom. The various signalling pathways which C-di-GMP modulates within bacteria are 
diverse but are usually linked to important lifecycle decisions (Krasteva et al., 2012) e.g. 
virulence factor expression, motility vs. senescence, biofilm formation  and , in the case of B. 
bacteriovorus ; the control of important decision checkpoints during the predation process 
(Hobley et al., 2012). 
C-di-GMP metabolism 
C-di-GMP synthesis and breakdown within bacteria is controlled by the opposing actions of 
two types of enzymes. Synthesis of C-di-GMP is controlled by a group of diguanylate 
cyclases which possess a common GGDEF domain while breakdown of C-di-GMP is 
controlled by phosphodiesterase enzymes which possess either EAL or HD-GYP domains 
(Krasteva et al., 2012). Homology searches have revealed that GGDEF, EAL and HD-GYP 
domains proteins are some of the most widely distributed proteins in the bacterial world 
(Römling et al., 2005). Bacterial genomes can contain multiple genes coding for many 
different C-di-GMP metabolising proteins, in addition some proteins exist which contain both 
GGDEF and EAL domains (Tal et al., 1998).  It is thought that this diversity is a result of the 
complexity of C-di-GMP mediated signalling in some bacteria and that the multiple proteins 
are required for the variety of pathways which C-di-GMP may control within a single cell 
(Römling et al., 2005) . 
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A single molecule of C-di-GMP is formed when two guanosine triphosphate (GTP) molecules 
are fused together via diguanylate cyclase activity. A GGDEF domain is about 180 residues in 
length and is defined by a Gly–Gly–Asp–Glu–Phe amino acid motif contained within the 
domain.  Each GGDEF domain acts as a  binding site for single GTP molecule and in addition 
possesses half of a catalytic site needed for full diguanylate cyclase activity (Römling et al., 
2005). Structural studies of the GGDEF diguanylate cyclase active site have revealed that the 
mechanism for C-di-GMP synthesis requires the dimerisation of two separate GTP bound 
GGDEF domain containing proteins; only upon dimerisation is the fully active catalytic site 
created (Chan et al., 2004).  
Degradation of C-di-GMP occurs via a hydrolysis reaction catalysed by the EAL or HD-GYP 
domain phosphodiesterase enzymes. During this reaction C-di-GMP is degraded into pGpG; 
further degradation from pGpG to GMP by EAL domain proteins has been observed, although 
the initial degradation step from C-di-GMP to pGpG is thought to be the rate limiting step of 
the reaction (Römling et al., 2005). A recent structural study which analysed multiple EAL 
domain proteins has suggested that the catalytic activity of EAL phosphodiesterases is 
dependent on the binding of two metal cations to conserved amino acid motifs within the 
EAL domain, these metal ions help to coordinate the positioning of a water molecule found 
bound to the active site which is needed for C-di-GMP cleavage (Tchigvintsev et al., 2010). 
The site which coordinates the binding of these cations is a conserved loop like structure 
within the EAL domain, metal ions commonly found bound to this loop are Mn
2+
 and Mg
2+
. 
The presence of the two coordinating cations helps to position a water molecule which, under 
catalytic conditions, is deprotonated to give a hydroxide ion (OH
-
) - this hydroxide group acts 
as a nucleophile and participates in a nucleophilic attack during the cleavage of C-di-GMP. 
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The final components in the C-di-GMP signalling system are the cellular elements which 
detect changing levels of C-di-GMP within the cytoplasm in order to propagate the signal to 
downstream processes, resulting ultimately in gene expression changes. Some of these C-di-
GMP sensing systems are proteins such as PilZ C-di-GMP receptors and degenerate GGDEF 
domain proteins. Both groups of protein bind C-di-GMP in order to activate downstream 
processes – e.g. activation of additional proteins within various signalling pathways (Römling 
et al., 2005). In addition to these protein based detectors, C-di-GMP signalling is also 
propagated by a group nucleic acid based detectors called riboswitches; these transcription 
like elements are regulated by C-di-GMP and facilitate changes in expression for a number of 
target genes both transciptionally and post transscriptionally (Krasteva et al., 2012). 
Bdellovibrio bacteriovorus specific -di-GMP proteins 
The B. bacteriovorus genome is currently known to encode at least 5 GGDEF domain 
proteins, 1 EAL domain protein, 5 HD-GYP domain proteins and 15 PilZ domain proteins 
(Hobley et al., 2012). C-di-GMP signalling in B. bacteriovorus offers an exciting opportunity 
to explore the basis of C-di-GMP signalling mechanisms shared throughout the bacterial 
kingdom, this is because although C-di-GMP appears to play an important role in B. 
bacteriovorus signalling (as evidenced by the relatively high number of PilZ receptors) the 
number of C-di-GMP metabolism proteins is relatively low. 
Initial knockout studies examining the 5 GGDEF domain proteins produced by B. 
bacteriovorus has been particularly fruitful. The five GGDEF domain proteins found in B. 
bacteriovorus have been designated DgcA (Bd0367), DgcB (Bd0742), DcgC (Bd1434), 
DgcD (Bd3766) and CdgA (Bd3125). Four of the five proteins, DgcA-D, have confirmed 
diguanylate cyclase activity as expected, however the fifth protein CdgA is not enzymatically 
active and may be a degenerative C-di-GMP cellular receptor. Interestingly it was found that 
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knockout mutants of four of the five genes – DgcA, DgcB, DgcC and CdgA – created in the B. 
bacteriovorus strain HD100 produced distinct phenotypes, each of which was related to a 
different part of the predatory lifecycle (Hobley et al., 2012). DgcA activity for example was 
found to be required for the control of B. bacteriovorus motility. Specifically knockout of 
DgcA rendered attack phase cells unable to swim in liquid culture or glide on solid surfaces 
(Hobley et al., 2012). Similar to flagella mutants previously discussed (Lambert et al., 2011) 
DgcA
-
 mutants could not hunt prey but could still invade cells if applied directly to the prey. 
This lack of flagellar or gliding motility also rendered newly septated progeny from exiting 
the Bdelloplast (Hobley et al., 2012). Unlike DgcA
-
 mutants, DcgB
-
 mutants did not have any 
ablation of motility; however they were nonetheless unable to invade prey cells – indicating 
that DcgB is required for initiation of prey invasion. Study of DcgC knockout mutants 
showed no deficiency in predation as observed with DgcA and DgcB knockout mutants, 
instead it was found that the rate at which attack phase cells converted to HI phase cells was 
significantly decreased. Finally the degenerate GGDEF CdgA was found to play a role in host 
invasion; unlike DcgB knockout mutants, CdgA knockout could still invade prey cells but the 
invasion was significantly slower – nearly doubling the average 30-40 minutes it takes 
between initial prey encounter and formation of the bdelloplasr (Hobley et al., 2012). 
It is surprising that knockout of four proteins which modify the levels of a single cytoplasmic 
signalling molecule could have such discrete and varied effects within a unicellular organism. 
A possible explanation for these discrete phenotypes can also be found in the study by Hobley 
et al., when they used fluorescently tagged versions of each GGDEF protein and found that 
each protein was localised to a specific area of the bacteria (Hobley et al., 2012). These 
observations support a model whereby there is not a single global C-di-GMP pool within 
bacteria, but rather a number of partitioned gradients within the cytoplasm. It is currently 
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thought that C-di-GMP is not freely diffusible within the cytoplasm but remains sequestered 
by C-di-GMP binding proteins which are targeted to different parts of the cell (Krasteva et al., 
2012). In this way multiple independent C-di-GMP gradients can be curated within the same 
cytoplasmic space by differentially distributed C-di-GMP metabolising proteins - for the 
purposes of modulating distinct C-di-GMP signalling pathways.  
Compared to what is known about the cellular functions of the 5 GGDEF guanylate cyclases 
little is known about the functional role of the six phosphodiesterase enzymes found in B. 
bacteriovorus. Although in depth phenotypic studies for these proteins have not yet been 
produced, a recent study has produced the first complete crystal structure of a B. 
bacteriovorus HD-GYP phosphodiesterase called Bd1817 (Lovering et al., 2011). This 
structure reveals a protein which possesses a C-terminal active site characterised by the 
binding of metal ions. The structure for Bd1817 is the first bacterial HD-GYP structure to be 
published, however Bd1817 in fact a degenerate protein and thus does not possess 
phosphodiesterase activity. With this in mind, the cellular function of Bd1817 is not known 
though it is thought it may as a ‘decoy’ enzyme by diluting out the effects of active enzymes.   
1.4 Project aims 
This study aims to build on and expand what it known about the functional characteristics for 
two C-di-GMP phosphodiesterase proteins – Bd2325 and Bd1971, which are found in B. 
bacteriovorus. This is a field of research which has already been advanced in recent years 
with the publishing of phenotypic and structural studies for B. bacteriovorus C-di-GMP 
related proteins (Hobley et al., 2012). The first of the proteins we propose to study is Bd2325, 
a 332 amino acid multi-domain HD-GYP protein which shares relatively close sequence 
homology with the previously mentioned B. bacteriovorus HD-GYP protein called Bd1817 
(23% identical residues, 47% similar residues). Unlike Bd2325, Bd1817 is an inactive, 
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degenerative HD-GYP while Bd2325 appears to be fully functional. If a functional structure 
for Bd2325 were to be determined it would be more biologically relevant compared to 
Bd1817 in terms of C-di-GMP signalling in B. bacteriovorus and also to the field of 
microbiology as a whole. This is because to our knowledge no complete protein structure for 
an active bacterial HD-GYP phosphodiesterase protein is currently available. 
Preliminary data from collaborators suggests that the biological role of Bd2325 in B. 
bacteriovorus is to control the switch between planktonic growth in liquid media and adherent 
growth on solid surfaces – this is because knockout mutants which lack Bd2325 expression 
can only be grown on solid agar. As well as improving our knowledge of C-di-GMP 
signalling, an understanding of this growth mechanism could prove extremely useful if B. 
bacteriovorus is ever adapted for use as an antibiotic. This is because a strain of B. 
bacteriovorus which can only grow on solid surfaces would allow the bacteria to be applied 
directly to wounds but would prevent the bacteria from growing within bodily fluids such as 
the blood which could cause undesirable treatment related complications.  
Previous attempts to purify and analyse Bd2325 by our group has been hindered because the 
full length recombinant protein will not express within E.coli. In this study we will therefore 
attempt to express a truncated form of Bd2325 which has been shortened at the N terminus 
such that it begins at threonine 22 – this truncation removes a section of Bd2325 sequence 
which has relatively poor homology to Bd1817 and in addition is not predicted to form any 
higher protein structures. The reasoning for this truncation is that while Bd1817 could be 
expressed Bd2325 cannot, therefore removal of this non homologous region from Bd1971 
could improve expression. If successful expression is achieved, we will attempt to purify and 
crystallise the protein with a view to obtaining a crystal structure. 
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The second protein we propose to study is Bd1971 which is an EAL phosphodiesterase 
enzyme. Bd1971 is a 400 amino acid 44.97 kDa protein which appears to have a two major 
domains connected by a linker region. The closest published homologous structure to the N 
terminal domain is a cyclic adenosine 3’,5’ monophosphate (cAMP) binding region from a 
human cGMP dependant protein kinase called 3OCP (Kim et al., 2011) (identical residues 37 
%, similar residues 62 %, DOI: 10.2210/pdb3ocp/pdb). The second, C terminal domain 
however belongs to an unpublished putative EAL / GGDEF protein from Thiobacillus 
denitrificans designated 2R60 (identical residues 37%, similar residues 56%) (DOI: 
10.2210/pdb2r6o/pdb). These two homology hits suggest that Bd1971 is a EAL 
phosphodiesterase protein which seems to be able to bind cAMP. Preliminary findings from 
phenotypic knockout experiments have found that B. bacteriovorus Bd1971 knockout strains 
clump together into matted structures when grown in suspension, attack phase cells 
occasionally break off from this structure however and are still fully predatory. As before with 
Bd2325 If we manage to purify the protein we will first attempt to acquire a crystal for 
structural determination, in addition to this we will also perform analyses to determine 
whether cAMP truly interacts with the protein. 
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Figure 2:  Domain diagrams and sequence alignments for Bd2325 and Bd1971 with their 
closest homologous partners. A) i. Domain diagram for Bd1971. Red domain = N –terminal 
domain predicted to bind cAMP; this domain has close homology to a cAMP binding domain 
in a cGMP dependant protein kinase called 3OCP found in humans (Kim et al., 2011) 
(Identical residues – 23%, similar residues – 46%, DOI:10.2210/pdb3ocp/pdb), residues 8 - 
85 in Bd1971 align with residues  122 - 195 in 3OCP. Green domain = C-terminal EAL 
domain; this domain has close homology to a number of EAL domain containing proteins, the 
best alignment comes from a GGDEF / EAL co-domain protein from Thiobacillus 
denitrificans called 2R60 (Identical residues – 37%, similar residues – 56%, DOI: 
10.2210/pdb2r6o/pdb), residues 142 - 400 in Bd1971 align with residues 487 - 740 in 2R60 – 
this region of 2R60 corresponds to its EAL domain. Between the cAMP binding and the EAL 
domains is a coiled coil region composed of two alpha helix domains (Bold line) at residues 
97- 114 and 134 – 156, between these two helices at residues 115 - 119 is a flexible linker 
sequence with the sequence ‘GGPGG’. A) ii. Sequence alignment report for Bd1971 (top 
row) and 2R60 (bottom row), residues 8-85 in Bd1971 align with residues 122-195 in 3OCP. 
A) i. 
Bd1971 
iii. 
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Red indicates good sequence homology while green indicates bad sequence homology. A) iii. 
Sequence alignment report for Bd1971 and 2R6O, 2R6) is homologous to the C-terminal 
domain from Bd1971 (37% identical residues, 56% similar identities), this domain in 2R6O 
represents an EAL domain. Red indicates good sequence homology while green indicates bad 
sequence homology. 
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B) i. Domain structure for Bd2325. Residues 1 - 21 are not predicted to form any higher 
structure. Residues 24 – 289 are homologous to a previously published crystal structure for a 
degenerative B. bacteriovorus HD-GYP protein called Bd1817 (Lovering et al., 2011) 
(Identical residues – 23% , similar residues – 47%, DOI: 10.2210/pdb3tm8/pdb). B) ii. A 
sequence alignment report for Bd2325 and Bd1817 (23% identical residues, 47% similar 
residues). Note the missing tyrosine (Y) residue in Bd1817 at the position 244, this residue is 
thought to be essential for HD-GYP activity. Red indicates good sequence homology while 
B) i. 
ii. 
Bd2325 
Ala332 
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green indicates bad sequence homology. Sequence homology reports (Aii,Aiii and Bii) were 
generated from the FASTA sequences of each sequence using TCoffee algorithms described 
here (Di Tommaso et al., 2011). 
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MATERIALS AND METHODS 
2.1 Bdellovibrio bacteriovorus protein expression 
N.B Expression vector construction and ‘manual’ IPTG induction (but not autoinduction) 
were kindly performed by Dr A. Lovering prior to the start of the study.  
The recombinant protein expression vectors used are given below; each vector was 
transformed into the lysogenised E.coli strain BL21-DE3 prior to recombinant expression.   
Bd2325
LF
, expression vector: pET28a, native full length Bd2325 protein with an N-terminal 
His-tag.  
Bd2325
SF
, expression vector: pET28a, Bd2325 protein, N-terminal truncation such that the 
protein starts at Thr22, N-terminal His-tag 
Bd1971, expression vector: pET41, native full length Bd1971 protein with a C-terminal 
thrombin cleavable His-tag.  
Bd1971
ALT
, expression vector: pET28a, native full length Bd1971 with a N-terminal His-tag. 
Manual induction 
The protocol used for these expressions is similar to one published previously (Lovering et 
al., 2011). Briefly 1 litre of culture medium was used for each expression run; this volume 
was split between two, two litre conical flasks – e.g. 500 ml per flask. The culture medium 
used was LB broth; each flask was supplemented with 500 μl kanamycin (Sigma Aldrich) 
(stock concentration - 50 mg per ml) to select for the growth of successfully transformed 
cells. Each culture was inoculated with the relevant E. coli strain - transformed with the above 
expression constructs. Inoculation was performed using overnight 10 ml mini cultures grown 
at 37
 o
C in half strength LB broth, 5 ml of this culture was added to 500 ml of LB broth 
(Sigma Aldrich) media. After inoculation the cultures were incubated first at 37 
o
C until they 
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reached an optical density of approximately 0.6 at 600 nm; expression was then induced via 
the addition of IPTG to the cultures which were then incubated overnight at 20 
o
C – 
throughout both incubations the flasks were shaken to promote aeration. After overnight 
incubation the cellular fraction of the culture media was extracted using centrifugation, the 
cell pellet was removed to a 50 ml plastic centrifuge tube and frozen at -80 
o
C for at least 24 
hours before being prepared for lysis and purification. 
Autoinduction 
The transformed E. coli strains (containing the recombinant expression vectors) used for the 
autoinduction protocol were the same as those used for the manual induction protocol 
described above. The composition of the media used for the autoinduction expression protocol 
was as follows: Yeast Extract 5 g/l, Tryptone 10 g/l , Na2HPO4 25 mM, KH2PO4 25 mM, 
NH4Cl 50 mM, MgCl2 2mM, 0.5 % glycerol, 0.05 % glucose, 0.2 % lactose, 0.5 ml / 100 ml 
trace metal stock solution for the full recipe, including the trace metal stock see (Studier, 
2005).  
Each expression was carried out in a total volume of 800 ml; this volume was split equally 
between two, two litre conical flasks. To inoculate the cultures, for each flask containing 400 
ml of media 4 ml of inoculate was added from a mini overnight culture of the relevant 
transformed E. coli strain – this mini culture was grown up in 10 ml half strength LB broth 
supplemented with 10 μl kanamycin (50 mg per ml) inside mini 25 ml conical flasks, 
inoculation of the transformed E. coli was performed from frozen glycerol stocks. The mini 
culture was left to grow over night at 37 
o
C with constant shaking. 
Following inoculation the flasks were warmed in a 37 
o
C incubator with constant shaking for 
2.5 hours for the cells to reach high density, they were then placed in a second incubator 
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cooled to 20 
o
C overnight – again with constant shaking. After overnight incubation the 
cellular fraction of the culture media was extracted using centrifugation, the cell pellet was 
removed to a 50 ml plastic centrifuge tube and frozen at -80 
o
C for at least 24 hours before 
being prepared for lysis and purification. 
2.2 Pre purification lysate preparation     
Cell lysis 
The cell pellet was removed from -80
o
C storage and left to thaw at room temperature, this 
thawing process was accelerated by the addition of approximately 40 ml room temperature 
lysis buffer – the lysis buffer was composed of our standard binding buffer or ‘Buffer A’ as it 
will be referred to, this buffer contained 30 mM Tris-HCL, 250 mM NaCl, 20 mM imidazole, 
5 % w/v glycerol and 5 % w/w sucrose, pH adjusted to give an overall pH of 7.95, with an 
additional 0.125 mg/ml lysozyme (Sigma Aldrich) and a single protease inhibitor cocktail 
tablet (Roche) added. Following addition of the lysis buffer, the tubes containing the lysate 
were left mixing on an automated tumbler for 45 minutes at room temperature. After this 
thawing period the lysate was chilled for 10 minutes on ice. Once chilled the cells within the 
lysate were lysed via sonication using a ‘Heat Systems – ultrasonic sonicator’ (Model W-25) 
tuned to give a total power output of 40 %. Sonication was performed in short bursts of 20 
seconds, leaving the cells to rest on ice between bursts to prevent unwanted heating of the 
cells and potential degradation of protein, this process was repeated a total of eight times.  
Lysate preparation 
Following cell lysis the lysate was clarified to remove cell debris and insoluble protein 
fractions. The chilled lysate then was decanted equally into two centrifuge tubes and 
centrifuged for 25 minutes at 15,000 g, 4 
oC in a Beckman JA20 rotor fitted to a ‘Beckman 
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Coulter Avanti J-25 centrifuge. This first centrifuge step was to remove heavy cell debris and 
will be referred to as the ‘soft spin’. Following centrifugation, supernatant from the soft spin 
was decanted equally into new centrifuge tubes and spun at 50,000 g, 4 
o
C in a Beckman type 
70-ti rotor fitted to a Beckman XL-90 Ultracentrifuge for 60 minutes - this faster centrifuge 
step referred to as the ‘hard spin’ was to remove much finer cell debris such as residual 
membrane fragments. The supernatant from the hard spin was carefully decanted off using a 
pipette into clean glassware and placed on ice - while removing the supernatant care was 
taken to avoid any disturbance of the pellet. This supernatant from step final step – the 
clarified lysate – will be referred to as the ‘onto’. 
2.3 Protein purification 
IMAC column purification 
Purification of the His-tagged recombinant protein – now referred to as the ‘ target protein’ – 
from the onto was achieved by passing the onto through a pre-prepared 1ml HisTrap HP 
immobilised metal affinity chromatography (IMAC) column (GE Healthcare Life Sciences, 
Product code: 17-5247-01), which had been equilibrated with 20 column volumes of Buffer 
A.  
The entire onto volume (usually 40 ml) was passed through the column using a peristaltic 
pump (GE Healthcare Lifesciences, model – Pump P-1) , a steady flow rate of around 1 ml a 
minute passing though the column was maintained to ensure that it was not subject to 
excessive pressure which would crush the sepharose resin. While the onto was being applied 
to the top of the column we collected what came off the bottom, we referred to this run off as 
the ‘flow through’ and it was reserved as a control for future analysis to ensure the target 
protein from the onto had bound to the column during purification. Once all of the onto had 
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been passed through the column we removed it from the pump and placed in the FPLC ÄKTA 
Prime (GE Healthcare Life Sciences) protein purification system. 
The FPLC was preloaded and pump washed with the ‘Buffer A’ previously mentioned and 
‘Buffer B’ – Buffer B being the same composition as Buffer A but with 300 mM imidazole 
instead of 20 mM. Throughout the FPLC purification procedure the relative magnitude of 
protein eluted from the column was measured using UV absorbance and all fractions eluted 
from the column were collected in 5 ml plastic test tubes. The pump was set to pump a 
volume of 1 ml buffer through the column per minute at a pressure of 0.5 MPa , we collected 
4.5 ml of eluted buffer per fraction (e.g. one 5 ml test tube with 4.5 ml elution buffer = one 
fraction). 
 In the first step the column was washed with a Buffer A to B ratio of 100 % to 0 % 
respectively until the absorbance peak reached a steady state – this was to ensure that all 
unbound protein was eluted from the column. Once the absorbance was once again level we 
upped the concentration of imidazole running through the column by altering the ratios of 
Buffer A and B to 87% and 13 % respectively – this helped to clean column of any protein 
which can bind weakly to the resin, again we waited until the change in absorbance peaked 
and then fell to a steady state. Once the column had been clean the ratios of Buffer A to B was 
altered to give a ratio of 0% to 100 % respectively. In these high imidazole conditions the 
His-tagged target protein was assumed to be eluted from the column – thus any peak in 
absorbance during the elution of these fractions inferred purified His-tagged protein. 
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2.4 Analysis of purified protein  
Preparation of purified protein          
Following elution from the HisTrap column, fractions containing the desired protein were 
further analysed using SDS-PAGE, the fractions which were assumed to contain protein were 
those that showed a peak in UV absorbance (as measured by the FPLC) under His-tag elution 
conditions – e.g. 100% Buffer B. Briefly samples from each elution peak were taken and 
loaded on an SDS-PAGE gel with an appropriate molecular weight marker (Fermentas, 
Thermo Scientific Catalogue No# SM0672). Fractions inferred to contain the desired protein 
were then determined by comparing the position of the protein bands with the markers to find 
the fractions whose band profile matched the molecular weight of the B. bacteriovorus 
protein. 
The fractions which were determined to contain the purified protein using UV absorbance and 
SDS-PAGE analysis were pooled and dialysed to remove imizazole before being 
concentrated. The selected fractions were pipetted into dialysis tubing and placed in the 
dialysis buffer – unless specifically stated this buffer consisted of 1 litre of ‘A’ binding buffer 
but with no imidazole added (e.g. 30 mM Tris-HCL, 250 mM Nacl, 5 % w/v glycerol and 5 % 
sucrose – pH 7.95). Dialysis was performed at 4 
o
C for a minimum of 3 hours. Following 
dialysis the solution was concentrated to an appropriate volume in order to give a protein 
concentration of between 10 – 20 mg per ml as determined by the Bradford protein 
concentration assay, comparing against a BSA standard. Concentration was performed using a 
spin concentrator (Vivaspin, 15ml)  
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Size exclusion chromatography 
To perform size exclusion chromatography, 4 ml of un-dialysed eluted fraction from FPLC 
protein purification was passed onto a gel filtration column loaded with sepharose. Following 
loading, filtered dialysis buffer (e.g. Buffer A with 0 mM imidazole) was passed through the 
column. Eluted fractions coming from the column were analysed for UV absorbance to 
indicate the presence of protein, those fractions which were determined to contain protein 
were analysed with SDS-PAGE. Fractions eluted during the ‘dead volume’ phase of elution 
from the column were assumed to be aggregated.  
Protein crystallisation screening 
To assess a broad range of different crystallisation conditions we used a number of 
commercially available crystallisation screens. Generally as an initial screen to judge the 
protein’s behaviour we used the Molecular Dimensions ‘Mini Screen’ which is largely based 
on the precipitant polyethylene glycol (PEG). If the protein appeared to behave well in this 
screen (e.g. limited protein aggregation) we proceeded to screen using the Molecular 
Dimensions ‘JCSG+’ screen which is also based largely on PEG as a precipitant. If the 
purified protein showed excessive aggregation in the ‘Mini Screen’ we instead moved to the 
Molecular Dimensions ‘Midas’ screen which screens against a number of alternative 
precipitants to PEG. Protein crystallisation of purified protein samples was performed using 
the hanging drop crystallisation method. Briefly 500 μl of each screening condition was 
loaded into the corresponding reservoir. On a plastic cover slip 1.5 μl of the purified protein 
was then mixed with 1.5 μl of the reservoir contents, this coverslip was then sealed over the 
reservoir with vacuum grease and the completed tray was left at 18 
o
C and check periodically 
for crystal growth.   
Robert Evans 
94 
 
Analytical ultracentrifuge analysis  
To prepare samples for analytical ultracentrifuge (AUC), the purified protein was diluted with 
dialysis buffer (e.g. Buffer A with 0 mM imidazole) to a protein concentration which gave an 
OD of 0.5 at 280 nm – this measurement was performed in a quartz cuvette. Samples with and 
without cAMP were measured using AUC, each sample was prepared to a volume of 500 μl.  
For samples with additional cAMP, we added cAMP (Sigma Aldrich, dissolved in sterile 
distilled water), to give a final concentration of 10 mM. Prepared samples were provided with 
blank controls (buffer only or buffer and cAMP) to the Birmingham Biophysical 
Characterisation Facility (BBCF) on the 7
th
 floor of Birmingham University Biosciences 
building to be analysed by sedimentation velocity AUC using a Beckman XL-I analytical 
ultracentrifuge.  
2.5 Inclusion body resolubilisation and refolding  
Inclusion body resolubilisation 
Insoluble protein fractions from the initial Soft Spin step of lysate preparation which were 
deemed to contain inclusion bodies were resolubilised in high concentrations of denaturant – 
either guanidine HCl or urea. The composition of these resolubilisation buffers was the same 
as Buffer A but with additional 6 M guanidine HCl or 8 M urea respectively.  
The resolubilsation buffer was added directly to the centrifuge tubes containing the pellet, the 
pellet was then mashed into small pieces using a metal spatula and then fully homogenised 
using a glass plunger homogeniser. Once fully homogenised the mixture was left to mix at 
room temperature for at least 12 hours on an automated tumbler. After this mixing period the 
mixture was centrifuged for 25 minutes at 15,000 g, 4 
o
C in a Beckman JA20 rotor fitted to a 
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‘Beckman Coulter Avanti J-25 centrifuge to remove any protein which still remained 
insoluble. 
Protein refolding 
We went about refolding the contents of the inclusion bodies by dialysing out the denaturant 
in two ways – we will refer to the first method as ‘shock dialysis’ and the second method as 
‘step dialysis’. 
Shock dialysis refolding first involved placing the supernatant from the final centrifuge step 
of inclusion body resolubilsation into dialysis tubing. This filled tubing was then placed in 1 
litre of dialysis buffer which contained no denaturant – this buffer was essentially Buffer A. 
Dialysis was performed in a two litre glass beaker with constant stirring of the dialysis buffer 
via a magnetic rod and stirrer at a constant temperature of 4 
o
C for at least 18 hours. After this 
time period the contents of the dialysis tubing were removed and centrifuged or 25 minutes at 
15,000g, 4
oC in a Beckman JA20 rotor fitted to a ‘Beckman Coulter Avanti J-25 centrifuge to 
separate the soluble fraction of the mixture from the insoluble aggregates which may have 
formed during removal of the denaturant. 
Step dialysis was similar to shock dialysis in that the supernatant from inclusion body 
resolubilsation was placed in dialysis tubing and then placed into dialysis buffer within a 
beaker with constant stirring. The difference however was that multiple dialysis conditions 
were used which reduced the molarity of denaturant in the dialysis buffer incrementally with 
each condition. In this protocol the amount of denaturant in the dialysis buffer was reduced by 
1 mole per step – e.g. 8 M  7 M  6 M etc. For each incremental step the contents of the 
dialysis tubing were allowed to sit for at least 2 and a half hours in each dialysis condition in 
order to fully equilibrate. 
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RESULTS 
3.1 – Bd2325 expression 
Previous attempts to purify recombinant full length Bd2325
LF
 (LF = “Longform”) from 
transformed E.coli culture have not been successful as the vector cannot be made to express 
Bd2325
LF
 in detectable quantities. Bd2325
LF
 has close sequence homology to another B. 
bacteriovorus protein Bd1817 which has been successfully in purified and crystallised 
previously (Lovering et al., 2011). Although the two proteins are similar, the first 21 N-
terminal residues in Bd2325
LF
 have relatively low similarity to Bd1817 (Figure 2B.ii). As this 
sequence is not found in Bd1817 - which does express in E.coli - it was reasoned that its 
removal from Bd2325
LF
 may improve recombinant expression, in addition this tail was not 
predicted form any higher structure so it was felt that its removal would not necessarily affect 
the global structure of Bd2325
LF
. The shortened version of Bd2325
LF
 was created prior to this 
study and shall be referred to as Bd2325
SF
 (SF = “shortform”) – this construct, kindly 
provided by Dr A. Lovering, is what we initially attempted to purify. 
Cell pellets from the Bd2325
SF
 pET28a expression construct transformed into E.coli were 
kindly provided pre-prepared for this study by Dr A, Lovering. The cells were cultured in 1 
litre of LB broth split between two, two litre conical flasks. The cells were grown at 37 
o
C 
until their density reached an OD of 0.6 at 600 nm, expression was then induced via the 
addition of IPTG to give a final concentration of 0.2 mM. Putative expression of Bd2325
SF
 
was detected using SDS-PAGE analysis of the cell lysates (data not provided).The cultures 
were then incubated at 20 
o
C overnight before the cell pellet was extracted using 
centrifugation.  
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3.2 Recombinant Bd2325
SF
 appears to be sequestered in insoluble inclusion 
bodies following expression in E. coli.  
Initial attempts to purify soluble Bd2325
SF
 from the prepared lysate onto were not successful. 
Following the initial ‘soft spin’ centrifuge step while preparing the cell lysate we observed 
that the insoluble pellet was large and had a very pale, almost white colour which is indicative 
of inclusion body formation. Inclusion bodies are cellular organelles that can sometimes form 
during recombinant protein expression; these structures sequester the recombinant protein 
within the normally insoluble lysate fraction, most often in an unfolded or mis-folded state 
(Tsumoto et al., 2003) . The absence of Bd2325
SF
 from the onto was confirmed following an 
unsuccessful purification attempt which elicited no significant bands in the elution fractions 
(Figure 3, lanes #10,#11 and #12), SDS-PAGE analysis of the onto lysate experimental 
control confirmed that there was no detectable Bd2325
SF
 within the soluble fraction of the cell 
lysate (Figure 3 , lane OT). Taken together this indicates that while the Bd2325
SF
 construct 
does express within E.coli, it is highly likely that most of the recombinant protein is insoluble 
and in a mis-folded state within inclusion bodies.  
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Figure 3: SDS-PAGE analysis following IMAC purification of Bd2325
SF 
from the soluble 
lysate fraction. Lane identities M = molecular weight marker, OT= ‘onto’, the lysate 
composition before passing onto the column, FT = ‘flow through’, the lysate composition 
after passing through the column, #n = the n
th
 elution fraction from the column – Red #n = 13 
% Buffer B vs. 87 % Buffer A. Green #n = 100% Buffer B vs. 0 % Buffer A. Loading volumes 
– M = 2.5 μl, OT and FT = 10 μl loaded into lane (1 in 20 dilution sample vs. SDS-PAGE 
loading buffer), #n = 10 μl loaded into lane (1 in 10 dilution  - sample vs. SDS-PAGE loading 
buffer). The red box indicates the bands of interest in the approximate weight range of 
Bd2325
SF
 (~38kDa) as indicated by the molecular weight marker control. 
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3.3 Bd2325
SF
 inclusion bodies can be solubilised in highly denaturing conditions.  
In an effort to purifiy Bd2325
SF
 from the insoluble pellet we next attempted to resolubilise the 
inclusion bodies under denaturing conditions before attempting to refold their protein contents 
in vitro into the correct conformation. To maximise our chances of successfully extracting 
Bd2325
SF
 from the inclusion bodies we chose to compare two commonly used denaturants – 
urea and guanidine hydrochloride (Gu-HCl) to ascertain which was the most effective at 
extracting Bd2325
SF
. Insoluble inclusion body pellets which were roughly the same weight (8 
M urea pellet – 2.17 g, 6 M Gu-HCl pellet – 2.49 g) from the ‘soft spin’ step of lysate 
preparation were resolubilised in Buffer A containing either 8 M urea or 6 M Gu-HCl. 
Following solubilisation for at least 18 hours the suspensions were centrifuged to remove all 
material within the lysate which still remained insoluble. Examination of the pellets produced 
by this step indicated to us that 6 M Gu-HCl seemed to be better at resolubilising the pellet 
compared to 8 M urea – as evidenced by the much smaller insoluble pellet following 6 M Gu-
HCl solubilisation compared to 8 M urea solubilisation (Figure 4A.i). 
3.4 Bd2325SF protein refolding shows varying success using different methods  
Following resolubilisation of the inclusion bodies we attempted to refold Bd2325
SF
 in vitro by 
gradually reducing the concentration of denaturant in the protein buffer. Preliminary attempts 
by us to refold Bd2325
SF 
via shock dialysis e.g. by placing the denatured protein (within 
dialysis tubing) straight into dialysis buffer with 0 M denaturant were not successful for either 
denaturant condition (data not shown). Near to the end of the dialysis time (roughly 16 hours 
out of 18) we observed large scale aggregation of the solubilised protein – indicative of 
unsuccessful folding due to the denatured protein being unable to cope with the removal of 
denaturing conditions. As a result of these initial experiments we adapted our technique and 
used a method taken from a study (Gupta et al., 2010) which managed to solubilise and refold 
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C-di-GMP metabolism proteins from E.coli inclusion bodies. This technique which, in this 
study will be termed ‘step dialysis’, differed from our initial refolding method as the 
denatured protein was incrementally dialysed  in a series of dialysis conditions - each with a 
slightly lower concentration of denaturant. Utilising this technique meant that we could better 
control the rate at which the denaturant was removed, and also if precipitation did occur we 
could pinpoint the concentration of denaturing agent at which it occurred much more readily.  
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Figure 4: Comparison of Bd2325
SF
 inclusion body resolubilisation using 8 M urea and 6 
M Gu-HCl. A) Two equally sized inclusion body pellets were resolubilised in 8 M urea (A.i) 
and 6 M Gu-HCl (A.ii) respectively. B) SDS-PAGE analysis of samples taken before and after 
step dialysis from 8 M urea and 6 M Gu-HCl experimental conditions. Lane identities – M = 
Molecular weight marker control, 8Ui = The remaining insoluble pellet following 
resolubilisation of inclusion body with 8 M urea, 8Us = Soluble sample taken following 
inclusion body resolubilisation with 8 M urea (e.g. the sample which went on to be dialysed), 
A) i. 
B)  
B) 
ii. 
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1Us = Sample of the protein which remained soluble following step dialysis from 8 M urea to 
1 M urea, 1Ui = Sample of the protein which did not remain soluble following step dialysis 
from 8 M urea to 1 M urea, 6Gi = The remaining insoluble pellet following resolubilisation of 
inclusion body with 6 M Gu-HCl, 6Gs = Soluble sample taken following inclusion body 
resolubilisation with 6 M Gu-HCl (e.g. the sample which went on to be dialysed), 0Gs Sample 
of the protein which remained soluble following step dialysis from 6 M Gu-HCl to 1 M Gu-
HCl, 0Gi = Sample of the protein which did not remain soluble following step dialysis from 8 
M urea to 1 M urea. Loading volumes – M = 2.5 μl, 8Ui, 8Us, 1Us, 1Ui, 0Gs and 0Gi = 10 μl 
loaded into lane (1 in 20 dilution, sample vs. SDS-PAGE loading buffer), 6Gi, 6Gs = 10 μl 
loaded into lane (1 in 40 dilution, sample vs. SDS-PAGE loading buffer). The red box 
indicates the bands of interest in the approximate weight range of Bd2325
SF
 as indicated by 
the molecular weight marker control. 
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Our preliminary experiments showed that if protein mis-folding and aggregation occur it 
usually did so in the final stages of shock dialysis (e.g. in the 1 M to 0 M denaturant range). 
To reduce the risk of aggregation during step dialysis we decided to remove the final traces of 
denaturant as quickly as possible. For this reason we decided to perform the final molar step 
(e.g. 1 M to 0 M urea) an IMAC column.  To do this ‘on column’ refolding as it is called; the 
1 M protein solution is bound onto a column equilibrated with a binding buffer with an equal 
denaturant concentration. Once the His-tagged protein is bound to the column a 0 M 
denaturant containing buffer is washed through the column to remove the final traces of 
denaturant. The bound protein is then eluted in 0 M denaturant conditions.  This ‘on column’ 
refolding technique could only be used for the 1 M urea condition as we found that Gu-HCl 
interferes with the binding of Bd2325
SF
 to the IMAC column. Therefore in the case of the Gu-
HCl condition we fully dialysed the solution to 0 M using the ‘step dialysis’ method.  
Following the completion of step dialysis (e.g. 8 M urea  1 M urea and 6 M Gu-HCl  0 M 
Gu-HCl) we observed a difference in the level of protein precipitation. Whereas the 1M urea 
solution a showed only minor clouding, the 0 M Gu-HCl condition was found to have large 
solid white clumps of aggregated protein floating within it – indicative of protein mis-folding. 
Both solutions were centrifuged to remove insoluble matter and then analysed using SDS-
PAGE to assess the amount of soluble protein left within either solution compared to that 
before dialysis. From this analysis we observed that for 8 M urea resolubilisation, although a 
significant amount of Bd2325
SF
 remained insoluble in 8 M urea (Figure 4.B Lane 8Ui) some 
of the protein was resolubilised (Figure 4.B Lane 8Us), and importantly a lot of this 
resolubilised protein remained soluble following step dialysis down to 1 M urea denaturant 
conditions. In comparison the Bd2325
SF
 which was resolubilised by 6 M Gu-HCl (Figure 4.B 
Lane 6Us) did not remain soluble following step dialysis down to 0 M Gu-HCl (Figure 4.B 
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Lane 0Us) and became mostly insoluble (Figure 4.B Lane 0Ui). N.B. The samples loaded into 
lanes 6Ui and 6Us, (Figure 4.B) had a twofold greater dilution factor than the other lanes on 
the gel – this is because high concentrations of Gu-HCl adversely reacted with the SDS-
PAGE loading buffer causing the sample to congeal; this meant a greater volume of SDS-
PAGE loading buffer was needed to sufficiently thin the sample for loading. Therefore the 
band sizes for 6Ui and 6Us are not directly comparable to the other lanes in the gel.  
Taken together our observations suggest that for Bd2325
SF
 inclusion bodies 8 M urea is the 
more suitable resolubilisation agent than 6 M Gu-HCl; this is because while 6 M Gu-HCl did 
manage to resolubilise the inclusion body pellet more efficiently than 8 M urea (Figure 4.A), 
protein denatured in Gu-HCl was more prone to aggregation and precipitation than urea when 
the denaturant was removed. Due the complete loss of soluble Bd2325
SF
 from the 0 M Gu-
HCl sample following step dialysis we chose to abandon this sample and concentrate on the 1 
M urea sample - which still contained detectable amounts of Bd2325
SF
 (Figure 4.B Lane 
1Us). 
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Figure 5 – SDS-PAGE analysis of the on column refold and purification of Bd2325SF from 
inclusion bodies resolubilised in 8 M urea. Lane identities M = molecular weight marker, 
OT= ‘onto’, the lysate composition before passing onto the column (1 M urea denaturing 
conditions), FT = ‘flow through’, the lysate composition after passing through the column (0 
M urea denaturing conditions), #n = the n
th
 elution fraction from the column – Blue #n = 0 % 
Buffer B vs.100 % Buffer A,  Red #n = 13% Buffer B vs.87 % Buffer A, Green #n = 100% 
Buffer B vs.0 % Buffer A. Loading volumes – M = 2.5 μl , OT and FT = 10 μl  loaded into 
lane (1 in 20 dilution, sample vs. SDS-PAGE loading buffer), #n = 10 μl loaded into lane (1 
in 10 dilution, sample vs. SDS-PAGE loading buffer). The red box indicates the bands of 
interest in the approximate weight range of Bd2325
SF
 as indicated by the molecular weight 
marker control. 
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As mentioned previously we chose to remove the final traces of urea (e.g. 1 M  0 M) using 
‘on column’ refolding. Following this on column refolding, the bound protein was eluted 
from the column and analysed using SDS-PAGE to determine if Bd2325
SF
 remained in the 
eluted fractions. This analysis firstly revealed that much of the Bd2325
SF
 which was present 
in the onto and was passed onto the column (Figure 5, Lane OT) did not bind to the column; 
this is because it could also be detected in the flow through control (Figure 5, Lane FT). 
Although not all of the protein had bound to the column, the SDS-PAGE analysis did show 
bands corresponding to the molecular weight of Bd2325
SF
 in three of the elution fractions 
(Figure 5, Lanes #7, #8 and #9). This indicates that we did manage to extract some soluble 
recombinant protein from the initial insoluble inclusion bodies – although the efficiency of 
the protocol was not great. 
Although this recovered protein remained soluble this was not sufficient evidence to prove 
that it had correctly refolding during removal of the denaturant. For this reason we subjected 
one of the eluted fractions (fraction #7) to size exclusion chromatography to see if the protein 
within the sample was the correct molecular weight for Bd2325
SF
, this result would indicate 
that the protein was properly folded and not aggregated. Unfortunately this analysis revealed 
that all of the protein within the sample could only be found at a molecular weight much 
greater than that predicted for Bd2325
SF
 and thus we concluded that mis-folding and 
aggregation had occurred. 
At this point we concluded that our attempts to resolubilise the contents of the inclusion 
bodies and refold them correctly were not likely to be successful. We have shown that it is 
possible to resolubilise the Bd2325
SF
 inclusion bodies using buffers containing 8 M urea and 
6 M Gu-HCl, however it appeared that the later removal of these denaturants caused protein 
mis-folding and aggregation – the opposite to what was needed. It may have been possible to 
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further refine our refolding protocols but given time restraints on the study we instead opted 
to change the initial protein expression conditions for Bd2325
SF
 in order to stop the formation 
of the inclusion bodies in the first place.  
3.5 An autoinduction expression protocol allows the expression of Bd2325
LF
 and 
improves the solubility of Bd2325
SF
 
To try and stop the formation of inclusion bodies, we decided to switch from induced 
expression protocol to a different technique called autoinduction. Induced expression 
protocols rely on an individual judging the right moment to induce recombinant protein 
expression by adding ITPG to the culture; in contrast to this, autoinduction allows the bacteria 
within the culture to induce recombinant protein expression themselves when the time is 
exactly right. This technique often improves protein yield as well as solubility of the 
recombinant protein. 
In addition to attempting soluble Bd2325
SF
 expression we also decided to test whether 
autoinduction would allow successful expression of the  Bd2325
LF
 expression construct – a 
feat which could not be accomplished using the standard induced expression protocol. 
Following autoinduction, SDS-PAGE analysis of cell lysate from Bd2325
SF
 and Bd2325
LF
 
autoinduction cultures both showed thick protein bands corresponding to the approximate 
weights of Bd2325
SF
 and Bd2325
LF
 respectively. Interestingly the band in the Bd2325
SF
 lysate 
lane ran slightly further into the gel than the corresponding band in Bd2325
LF
, this 
observation agrees with the fact that Bd2325
SF
 is shorter than Bd2325
LF
 and as such has a 
lower molecular weight. This is quite convincing evidence that both of the expression 
constructs expressed Bd2325 during autoinduction which is especially significant for 
Bd2325
LF
 as it is the first time the expression construct has properly worked.  
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Figure 6: SDS-PAGE analysis of cell lysate from two Bd2325 autoinduction expression 
experiments. Lysates from Bd2325
LF 
(lane 1 and 2) and Bd2325
SF
 (lane 3 and 4) 
autoinduction expression runs. Lane identities: M= molecular weight marker, 1 = raw cell 
lysate from Bd2325
LF
 culture, lysed in 400 μl bugbuster per 3 ml of pelleted culture. 2 = 
soluble fraction from Bd2325
LF
 raw cell lysate following centrifugation, 3 = raw cell lysate 
from Bd2325
SF
 culture, lysed in 400 μl Bugbuster Protein Extraction Reagent (Novagen)   per 
3 ml of pelleted culture, 4 = soluble fraction from Bd2325
SF
 raw cell lysate following 
centrifugation. Loading volumes: M = 2.5 μl loaded into lane, 1-4 = 10 μl loaded into lane (1 
in 4 dilution. Sample vs. SDS-PAGE loading buffer). The red box indicates the bands of 
interest in the approximate weight range of both Bd2325 versions as indicated by the 
molecular weight marker control.  
 
 
Bd2325
LF Bd2325
SF 
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Following two promising protein expression experiments we went on to attempt to purify 
Bd2325
LF
 and Bd2325
SF
 from their respective cell lysates. We first attempted to purify 
Bd2325
LF
 which, until the use of autoinduction we had not managed to express successfully 
in E.coli.  During elution of Bd2325
LF
 from the IMAC column we did not see any significant 
peaks in UV absorbance in the fractions where you would expect His-tagged protein elution 
to occur (e.g. 100% Buffer B). SDS-PAGE analysis of these eluted fractions confirmed to us 
that we had been unsuccessful in isolating Bd2325
LF
 from the onto (Figure 7A.ii Lanes #15, 
#16, #17 and #18); as there were no visible bands in these fractions corresponding to the 
molecular weight of Bd2325
LF. To determine at which point during the protocol we ‘lost’ 
Bd2325
LF
, we studied the onto and flow through controls (Figure 7A.ii. Lanes OT and FT) as 
well as sample controls which were taken during the preparation of the cell lysate for 
purification (Figure 7A.i). These controls suggested that the majority of initially expressed 
Bd2325
LF
 remained in the insoluble fractions of the lysate e.g. the pellets following the soft 
spin and hard spin steps of lysate preparation (Figure 7A.i. Lanes Si and OTi). Thus the 
absence of Bd2325
LF
 in the eluted fractions was due to there being no Bd2325
LF
 within the 
onto which was pumped onto the IMAC column (Figure 7A.ii. Lane OT). From this failed 
purification we can conclude that although autoinduction allowed successful expression of the 
Bd2325
LF
 construct in E.coli, the recombinant protein expressed was in some way insoluble 
and thus could not be extracted using IMAC purification.  
Following our attempts to purify Bd2325
LF
 we next tried the prepared Bd2325
SF
 lysate from 
the autoinduced cells. During lysate preparation we observed that we did not get the large pale 
insoluble inclusion body pellets which occurred following manual expression induction; this 
observation suggested to us that autoinduction had improved the solubility of Bd2325
SF
. SDS-
PAGE analysis of samples taken during lysate preparation confirmed that solubility of 
Robert Evans 
110 
 
Bd2325
SF
 had improved (Figure 7B.i); this was illustrated by a thick clear band corresponding 
to the molecular weight of Bd2325
SF
 which could be seen in the soluble fraction of the lysate, 
following the initial soft spin centrifuge step (Figure 7B.i. Lane Ss). Furthermore this band 
was not present in the insoluble pellet from the same centrifugation step (Figure 7B.i. Lane 
Si). Taken together this indicated that when expressed using autoinduction Bd2325
SF
 seemed 
to remain soluble during lysate preparation – a different fate to previous manual induction 
attempts which saw Bd2325
SF
 remain sequestered inside insoluble inclusion bodies. 
Although the solubility of Bd2325
SF
 seemed to have been improved by autoinduction, when 
we progressed to attempting to purify the protein using IMAC the results were not so 
promising. SDS-PAGE analysis of the purification attempt (Figure 7B.ii.) revealed a thick 
band of protein at the right molecular weight for Bd2325
SF
 in the onto control (Figure 7B.ii. 
Lane OT) suggesting that soluble Bd2325
SF
 entered the column, in addition this same band 
was not detectable in the flow through control (Figure 7B.ii. Lane FT) suggesting the His-
tagged protein bound to the column once it was applied. Due to the fact that Bd2325
SF
 was 
applied to the column and was not present in the flow through, it was surprising that we could 
not detect any traces of the protein in our elution fractions, which corresponded to the peak in 
UV absorbance during 100% Buffer B elution conditions (Figure 7B.ii. Lanes #13 and #14). 
From this analysis we can only conclude that Bd2325
SF
 must for some reason remain bound 
to the column even under conditions which normally would have eluted a His-tagged protein 
from the Ni
+
 charged HisTrap column.       
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Figure 7: SDS-PAGE analysis of IMAC purification experiments for Bd2325
LF
 and 
Bd2325
SF
- A) SDS-PAGE analysis of autoinduced Bd2325
LF
 purification. B) SDS-PAGE 
analysis of autoinduced Bd2325
SF
 purfication. A.i) and B.i) - Samples taken during lysate 
preparation. Lane identities: M = Molecular weight marker control, L = lysate sample – 
taken following sonication of cell pellet, Si = Soft spin insoluble fraction – taken from the 
pellet following the initial soft spin centrifuge step, Ss = Soft spin soluble fraction – taken 
from the supernatant following the initial soft spin centrifuge step, OTi = Onto insoluble 
fraction – taken from the insoluble pellet following the final hard spin centrifuge step. 
A i) ii) 
ii) i) B 
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Loading volumes – M = 2.5 μl loaded. L, Si, Ss and OTi 10 μl loaded (1 in 4 dilution sample 
vs. SDS-PAGE loading buffer) A.ii) and B.ii) - Samples taken during IMAC purification. Lane 
identities: M= Molecular weight marker control, OT= ‘onto’, the lysate composition before 
passing onto the column, FT = ‘flow through’, the lysate composition after passing through 
the column, #n = the n
th
 elution fraction from the column – Blue = 0 % Buffer B vs. 100 % 
Buffer A. Red = 13% Buffer B vs. 87% Buffer A. Green = 100% Buffer B vs. 0% Buffer A. 
Loading volumes – M = 2.5 μl loaded , OT and FT = 10 μl  loaded into lane (1 in 4 dilution  
sample vs. SDS-PAGE Loading buffer), #n = 10 μl loaded into lane ( 1 in 2 dilution sample 
vs. SDS-PAGE  Loading buffer ). The red box indicates the bands of interest in the 
approximate weight range of Bd2325
SF
 as indicated by the molecular weight marker control. 
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3.6 – Bd1971 expression 
Previous attempts by our group to purify Bd1971 have not been successful; although the 
initial expression and purification appears to work well the protein does not remain stable 
once it is eluted from the IMAC column and the imidazole is dialysed away. These 
purification attempts used the expression vector pET41 which gave the recombinant protein a 
C-terminal His-tag. To ascertain if the position of the His-tag was interfering with the stability 
of Bd1971 we decided to use an alternative expression construct using the vector pET28a 
which gave Bd1971 an N-terminal His-tag (This construct was kindly provided by Dr A. 
Lovering) – the recombinant protein produced with this alternative tag was called Bd1971ALT 
to differentiate it from our initial construct.      
3.7 An alternatively positioned His-tag does not improve the stability of Bd1971  
We attempted to purify the His-tagged protein from the onto prepared from the crude cell 
pellet (Cell pellet again kindly provided by Dr A. Lovering) by the aforementioned protocol. 
During elution from the column under 100% Buffer B conditions we observed a very high 
peak in UV absorbance which was indicative of large amounts of eluted protein from the 
column. SDS-PAGE analysis of these eluted fractions showed a very clean, thick band of 
protein in the fractions from the 100% Buffer B elution peak, at the correct molecular weight 
for Bd1971
ALT
; as indicated by the molecular weight marker control lane. Taken together this 
data provided very convincing evidence to us that we had managed to purify Bd1971
ALT
 from 
the cell lysate. 
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Figure 8: SDS-PAGE analysis following IMAC purification of Bd1971
ALT 
from the 
soluble lysate fraction - Lane identities M = molecular weight marker, OT= ‘onto’, the 
lysate composition before passing onto the column, FT = ‘flow through’, the lysate 
composition after passing through the column, #n = the n
th
 elution fraction from the column - 
red = 13% Buffer B vs. Buffer A, green = 100% Buffer B vs. Buffer A. Loading volumes – M 
= 2.5 μl , OT and FT = 10 μl  loaded into lane (1 in 20 dilution, sample vs. SDS-PAGE 
loading buffer), #n = 10 μl loaded into lane (1 in 10 dilution , sample vs. SDS-PAGE loading 
buffer). The red box indicates the bands of interest in the approximate weight range of 
Bd2325 as indicated by the molecular weight marker control. 
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Of the three elution fractions which we had previously determined to contain purified 
Bd1971
ALT
 (Figure 8, lanes #15, #16 and #17) we decided to prepare fractions #15 and #16 
for protein crystallisation e.g. dialysis to remove imidazole and spin concentration whereas 
fraction #17 would be analysed using size exclusion chromatography to determine if the 
eluted protein was properly folded or composed of mis-folded aggregates. Unfortunately 
while handling fractions #15 and #16 we found that the instability which plagued our earlier 
experiments remained; the protein within the pooled fractions precipitated firstly during 
dialysis and then again during concentration of the remaining soluble fraction leaving us with 
negligible amounts of protein – we therefore abandoned our attempts to perform analyses 
using this sample. Size exclusion analysis of the remaining fraction #17 indicated to us that 
the protein within the fraction was in a single, large molecular weight clump much larger than 
the expected size of Bd1971
ALT
 – indicative of protein aggregation. Through consideration of 
both the inherent protein instability post elution and this size exclusion data we concluded that 
the use of an alternatively located His-tag had not improved the structural stability of Bd1971. 
The size exclusion analysis of Bd1971
ALT
 indicated to us that the problems we’d encountered 
with Bd1971 thus far may have been due to mis-folding and or aggregation of Bd1971. Our 
earlier successes with getting soluble Bd2325 expression using the autoinduction method lead 
us to wonder if, by applying this expression method again we could improve the stability of 
Bd1971. 
3.8 Autoinduction expression of Bd1971 significantly improves protein stability  
For autoinduction expression we chose to use the original expression construct with a C-
terminal tag, this was because the C-terminal His-tag had the potential of being cleaved from 
the protein using thrombin if the purification was successful, which we saw as another 
possible avenue to improve protein stability. SDS-PAGE analysis of the raw cell lysates 
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following autoinduction suggested that expression of soluble Bd1971 using this method was 
possible, as illustrated by the large protein band corresponding to the rough molecular weight 
of Bd1971 on the gel.  
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Figure 9 – SDS-PAGE analysis of Bd1971 expression using autoinduction and its subsequent 
purification using IMAC purification. A) SDS-PAGE Analysis of lysate from the Bd1971 
autoinduction expression run. Lane identities = M = Molecular weight marker control, 1 = 
raw cell lysate from Bd1971 autoinduction culture, lysed in 400 μl bugbuster per 3 ml of 
pelleted culture. 2 = soluble fraction from Bd1971 raw cell lysate following centrifugation. B)  
SDS-PAGE analysis of Bd1971 purification following autoinduced expression. Lane 
identities, M = molecular weight marker, OT= ‘onto’, the lysate composition before passing 
onto the column, FT = ‘flow through’, the lysate composition after passing through the 
column, #n = the n
th
 elution fraction from the column – Blue = 0 % Buffer B vs. 100 % Buffer 
A, Red = 13% Buffer B vs. Buffer A, Green = 100% Buffer B vs. Buffer A. Loading volumes – 
M = 2.5 μl , OT and FT = 10 μl  loaded into lane (1 in 2 dilution, sample vs. SDS-PAGE 
loading buffer), #n = 10 μl loaded into lane (1 in 2 dilution, sample vs. SDS-PAGE loading 
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buffer). The red box indicates the bands of interest in the approximate weight range of 
Bd1971 as indicated by the molecular weight marker control. 
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The presence of large amounts of soluble Bd1971 was further suggested following a 
successful IMAC column purification in which we observed a high UV absorbance upon 
target protein elution conditions e.g. 100% Buffer B – SDS-PAGE analysis of the eluted 
fractions detected a very large single band of protein at the correct molecular weight for 
Bd1971. Taken together this is compelling evidence that using autoinduction expression we 
were able to purification large amounts of relatively pure Bd1971. Importantly the protein 
within the eluted fractions remained stable throughout imidazole dialysis – a feat which could 
not be claimed for Bd1971 produced using manual induction. Following complete removal of 
imidazole from the sample, we used a Bradford’s protein concentration assay to determine the 
protein concentration within the sample which was already 20 mg per ml. Due to the 
concentration of the sample already being sufficient for protein crystallisation concentration 
of the sampe was not needed – omission of the concentration step is highly unusual and 
empathises the very large amounts of protein which were produced during autoinduction 
expression. 
3.9 Bd1971 – purified protein analysis  
We next attempted to crystallise the purified protein using a number of commercially 
available chemical screen kits. Crystallisation was attempted using the hanging drop method, 
each reservoir was filled with 500 μl screening solution and a drop composed of 1.5 μl 
undiluted (e.g. 20 mg/ml) protein and 1.5 μl screening solution was suspended above on a 
plastic coverslip, sealed down with vacuum grease. We first tried the 24 well ‘Mini Screen’ 
from Molecular dimensions; this screen largely uses polyethylene glycol (PEG) as a 
precipitant. No crystal hits were obtained from this screen and in addition many of the 
conditions produced a thick brown precipitate in the drop. The magnitude of precipitation 
indicated to us that Bd1971 crystal formation was not likely to occur in PEG, so we next 
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switched to the Molecular Dimensions ‘Midas’ screen which tests for many different 
precipitating compounds, unfortunately again no crystal hits were acquired and as before the 
majority of screening conditions produced thick brown precipitates.  
The unstable nature of Bd1971 during our crystallisation screens led us to think that perhaps 
the C-terminal His-tag attached to the protein to facilitate purification may be interfering with 
crystal formation by preventing ordered molecular alignment in the crystal. Fortunately the C- 
terminal His-tag that was attached to Bd1971 was cleavable using thrombin, we therefore 
treated an aliquot of our protein sample with restriction grade thrombin (EMD Millipore, 
catalogue).  To ensure excess thrombin we added 0.5 μl of the stock enzyme for every 100 μl 
of protein sample. 
To assess the success of His-tag cleavage we ran SDS-PAGE analysis of samples taken from 
the protein sample before thrombin addition, 24 hours after thrombin addition and 72 hours 
after thrombin addition – we reasoned that cleavage of the His-tag would reduce the 
molecular weight of Bd1971 and thus could assess His-tag cleavage using SDS-PAGE by 
comparing how far into the gel each sample had run. From this analysis we determined that 
complete cleavage of the His-tag had not occurred by 24 hours (Figure 10 lane 3), however by 
72 hours the majority of protein within the sample appeared to be of a smaller molecular 
weight (Figure 10 lane 4).   
Following successful cleavage of the His-tag from Bd1971 we repeated the same 
crystallisation screens that we used before, we observed that the performance of the protein 
improved slightly e.g. it did not precipitate in as many screening conditions as before. 
Unfortunately however we did not manage to obtain any crystal hits in the screens which we 
performed.               
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Figure 10 – SDS-PAGE analysis of Bd1971 before and after His-tag cleavage with 
thrombin. The C-terminal His-tag attached to purified Bd1971 was cleaved using thrombin, 
to assess the success of cleavage protein samples were taken before and after the addition of 
thrombin – successful cleavage is assumed for samples which have a lower molecular weight 
than the pre thrombin control. Lane identities – M) Molecular weight marker control, 1) 
Bd1971 pre thrombin control 1 – sample taken immediately following protein purification and 
imidazole dialysis. 2) Bd1971 pre thrombin control 2 – sample taken just before the addition 
of thrombin, this sample is approximately 24 hours older than lane 1. 3) Bd1971 + thrombin 
– sample taken 24 hours after the addition of thrombin. 4) Bd1971 + thrombin – sample taken 
72 hours after the addition of thrombin. Loading volumes – M = 2.5 μl loaded, 2, 3 and 4 = 
10 μl loaded (1 in 20 dilution, sample vs. SDS-PAGE loading buffer). 
 
 
3.10 Preliminary AUC analysis of Bd1971 shows possible oligomeric state 
changes in the presence of cAMP 
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It has been stated previously that an N-terminal region of Bd1971 from residue 8-85 is highly 
homologous to a cAMP binding domain from a human cGMP dependant protein kinase 
designated 3OCP (Kim et al., 2011) (Figure 2A.ii). This homology leads us postulate that 
cAMP may in some way interact with Bd1971 and somehow modulate its function. With this 
in mind we wished to determine whether the addition of cAMP to Bd1971 could lead to a 
change in oligomerisation e.g. the change from a monomer to a dimer or vice versa. To 
perform this analysis we chose to use sedimentation equilibrium analytical ultracentrifugation 
which allows the molecular weight of protein complexes in solution to be determined – as 
each Bd1971 monomer has a molecular weight of ~45 kDa; therefore oligomerisation can be 
inferred by mass peaks which are multiples of this weight.  
AUC samples containing purified Bd1971 were prepared both with and without cAMP at 
varying concentrations. It must be noted that the addition of cAMP to the samples seemed to 
interfere with data acquisition, for this reason we were only able to successfully process data 
for two conditions – one un thrombinised Bd1971 sample (e.g. with His-tag attached) with 10 
mM cAMP and one thrombinised Bd1971 sample (e.g. without His-tag attached) without any 
additional cAMP added. For this reason and because of the aggregative unstable nature of 
Bd1971 this AUC data is considered preliminary. 
 
 
 
 
 A) 
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Figure 11 – AUC analysis of Bd1971 with and without the addition of cAMP. A) AUC 
analysis of Bd1971 (with His-tag) without the addition of cAMP, peaks along the x-axis 
correspond to populations within the solution with different molar masses (Da). The two 
arrows mark the peaks of interest with ~45 kDa and ~90 kDa molar masses respectively – 
these two peaks may represent monomeric and dimeric Bd1971 respectively. B) AUC analysis 
of Bd1971 (without His- tag) with additional cAMP added (10 mM). The X-axis represents the 
sedimentation coefficient of different populations within the solution, to allow peak 
comparison with A) the molar masses for the peaks have been calculated, the two peaks of 
interest are marked with arrows and annotated.       
 
Although we cannot currently infer definitive conclusions from the AUC analysis it is 
possible to discern distinct populations of protein within the sample which correspond to the 
 
40 kDa 80 kDa 
38.3 kDa 
kDA 
91.9 kDa 
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B) 
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molar masses 45 kDa and 90 kDa respectively (figure 11). It is therefore possible that the 45 
kDa peak represents Bd1971 in a monomeric form and the 90 kDa peak in its dimeric form. 
Importantly the size of the respective populations seems to change between the sample which 
has additional cAMP and the control sample which does not. This indicates that the 
oligomeric state of Bd1971 may change when cAMP is present. 
The data presented above seems to indicate that Bd1971 may form into a dimeric state when 
cAMP is added to the solution (figure 11.B); this conflicts with data which was acquired by 
Dr A Lovering following completion of the experimental stages of this study. This analysis 
used small angle x-ray scattering to analyse Bd1971 and produced evidence to suggest that in 
fact Bd1971 naturally forms a dimer in solution which is broken apart upon the addition of 
cAMP. With this in mind and considering the unstable nature of purified Bd1971 we can only 
conclude at this point that cAMP may cause a switch between monomeric and dimeric states, 
however the direction of this state switch is yet to be conclusively determined.    
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DISCUSSION  
4.1 Bd2325 
Bd2325
LF 
and Bd2325
SF
 expression using manual induction 
In this study we found that N-terminal truncation of the native length Bd2325
LF 
from Met1 to 
Thr21 allowed expression of the recombinant protein (albeit mis-folded) where before no 
expression could be detected. This success suggests that something about the full length 
Bd2325
LF
 - and more specifically the 21 amino acid sequence which was removed from it, 
somehow prevents recombinant expression. It must be noted however that although truncation 
improved Bd2325 expression, the protein produced remained within inclusion bodies - most 
likely in a mis-folded form. Thus the truncation of Bd2325
LF
 to Bd2325
SF
 may have allowed 
for recombinant expression but it did not allow us to easily purify the protein later on (Figure 
3). The reason for inclusion body formation is unclear; it could be that truncated Bd2325
SF
 
expressed too highly leading to overloading of translational machinery. The stress this may 
have put on the E.coli could have lead to the recombinant protein being sequestered into 
inclusion bodies – this is a very likely outcome for recombinant expression when it is too high 
(Singh and Panda, 2005). It is possible that the truncation lead to structural instability in the 
protein, leading to mis-folding and inclusion body formation. With the latter theory in mind, a 
possible model exists which nicely tying together both forms of Bd2325 - it could be that both 
Bd2325
LF
 and Bd2325
SF
 can be expressed in E.coli but only Bd2325
SF
 is produced in 
detectable quantities. This is because biologically active Bd2325
LF
 is toxic to E.coli and as 
such kills the cells which express it while conversely Bd2325
SF
 can accumulate in culture 
because it is mis-folded, functionally inactive and thus is not toxic to E.coli 
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Inclusion body resolubilisation and in vitro refolding 
Our attempt to resolubilise the inclusion bodies formed as a result of Bd2325
SF
 expression 
was partly successful. Through comparison of two denaturing conditions – 8 M urea and 6 M 
Gu-HCl – we found that 6 M Gu-HCl was possibly more effective at solubilising the 
inclusion bodies compared to 8 M urea (Figure 4A). When we later went on to refold the 
denatured protein by removing the denaturants however we found that protein solubilised in 6 
M Gu-HCl was more prone to aggregation at lower molar ranges of denaturant compared to 8 
M urea. This lead us to conclude that overall 8 M urea was a better candidate for Bd2325
SF
 
inclusion body resolubilsation. While the recovery of protein from the inclusion body pellet 
was lower for urea than Gu-HCl we were nonetheless able to isolate some soluble protein 
from the urea solubilised sample following removal of the denaturant (Figure 4B Lane 1Us) – 
a result which could not be achieved for Gu-HCl (Figure 4B Lane 0Gs). 
Following inclusion body resolubilisation and in vitro refolding via ‘step dialysis’ we found 
that we had soluble protein remaining in the sample which had been solubilised in 8 M urea 
(Figure 4B lanes 1Us). This sample was passed onto a IMAC column and relatively pure His-
tagged Bd2325
SF
 was eluted (Figure 5). Unfortunately size exclusion analysis for one of the 
eluted fractions revealed that even though the eluted protein was soluble it was still mis-
folded and aggregated. From these results we concluded that resolubilisation of inclusion 
bodies was possible using 8 M urea but currently the denatured protein could not made to 
refold correctly.  
Although we did not manage to properly refold the contents of the inclusion bodies in this 
study, it is conceivable that further work to optimise the in vitro refolding protocol could 
prove fruitful. One of the improvements which could be made to our protocol would be the 
supplementation of the dialysis buffer with additional compounds to facilitate refolding. The 
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purpose of these additives could either be to prevent protein aggregation or to encourage 
correct protein re-folding. Our dialysis buffer did in fact contain sucrose (5 % w/v) which is 
known to encourage formation of the stable fully folded protein structures, thus the addition 
of an aggregation inhibitor such as polyethylene glycol or arginine HCl could have reduced 
the level of protein aggregation which we observed during refolding. These aggregation 
inhibitors function by preventing interactions between partial refolded protein molecules 
which can disrupt refolding and lead to aggregation (Tsumoto et al., 2003). Another 
improvement which could be made is to optimise the mode of dialysis used to remove the 
denaturant. In this study we found that quickly dialysing the denaturant using ‘shock dialysis’ 
lead to protein aggregation during refolding so we switched to a slower, more controlled ‘step 
dialysis’ method - however this method also lead to aggregation. It is possible that a middle 
ground exists between the two dialysis methods – this method would remove the denaturant at 
the correct rate to stimulate protein refolding while also preventing aggregation. With this in 
mind, one route of optimisation could be to adjust our step dialysis to find the correct dialysis 
speed. For instance the dialysis process could be sped by increasing the molar step between 
each dialysis condition e.g. to 2 M per step (e.g. 8 M  6 M  4 M etc.).  
Bd2325
SF
 and Bd2325
LF
 expression using autoinduction 
Following our failure to isolate Bd2325
SF
 from inclusion bodies we went back to our initial 
expression protocol to see if we could improve recombinant expression such that the inclusion 
bodies would not form in the first place. In this respect we found that switching manual 
induction expression for autoinduction improved recombinant expression for both forms of 
Bd2325 quite noticeably in this study - firstly it allowed us for the first time to express 
Bd2325
LF
 (Figure 6 lanes 1 and 2) and secondly it improved the solubility of Bd2325
SF
 by 
ablating the formation of inclusion bodies (Figure 7B.i lane Si). It must be noted however that 
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we were still unable to purify either form of Bd2325 from prepared lysate; Bd2325
LF
 
autoinduction allowed protein expression but the recombinant protein remained in some way 
insoluble during lysate preparation (Figure 7A.i lane OTi), while for Bd2325
SF
 the protein 
appeared soluble but could not eluted from the IMAC column (Figure 7B.ii). From this we 
conclude that the fate of both forms of Bd2325 following autoinduction indicate that the 
protein is still mis-folded following recombinant expression.  
The principles of autoinduction  
The question still remains though how switching to autoinduction improved protein 
expression - to explain this, an understanding of autoinduction and the inducible lac operon 
(used in our expression vectors) is needed.  Autoinduction expression relies on the principle 
that E.coli can utilise different energy sources, switching from a preferred substrate to a less 
preferred substrate once the first is fully utilised – this is called diauxic growth. In the case of 
E.coli this means that glucose is metabolised in preference to lactose which is only 
metabolised when glucose is depleted- this is because lactose requires more energy 
investment to metabolise. Diauxic growth in E.coli is controlled by the lac operon. Briefly 
when glucose is being metabolised, expression of the lactose metabolising enzyme β-
galactosidase - coded for by the gene lacZ - is suppressed by a constitutively expressed gene 
repressor protein coded by lacI – another lac operon gene. When E.coli runs out of glucose, 
allolactose – a metabolite of lactose - causes lacI inhibition of lacZ to be circumvented 
allowing lacZ expression thus allowing E.coli to utilise lactose in its environment.  
Expression of lacZ is further stimulated by a spike in cellular cAMP levels triggered by the 
lack of glucose in the medium. This cAMP starvation response activates the ‘cAMP receptor 
protein’ (CRP); CRP is an activator protein which binds to the lac operon, further boosting 
lacZ expression (Wilson et al., 2007).  
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Recombinant protein expression technology has taken the lac operon and modified it to create 
an inducible expression system. Many expression vectors (including those used in this study) 
contain a modified copy of the lac operon which has had the coding region of lacZ replaced 
with a cloned gene for the recombinant protein to be expressed. The expression vector is 
cloned into an E.coli strain which is then grown in bulk culture. When the culture has reached 
the correct stage of growth – usually the log phase – expression of the recombinant gene is 
activated by the addition of IPTG; IPTG is an artificial analogue of allolactose and thus 
activates expression of the modified lacZ gene. This ‘manual’ IPTG induction method is what 
was initially used to produce the recombinant B. bacteriovorus proteins for this study. IPTG 
induction was initially used because it generally produces successful results and uses standard 
commercially available culture media – in our case LB broth. However this method does not 
faithfully replicate wild type lac induction as IPTG is added when glucose is still available in 
the medium. This means that the normal cAMP response is not activated and in addition one 
must judge the correct time point to add IPTG. The result of misjudged IPTG induction is that 
the expressing cells are often unnaturally shocked into expression at the incorrect time – thus 
this method requires careful optimisation to obtain good results.  
Switching to autoinduction allowed us to produce a more natural lac operon induction 
process. Autoinduction uses a defined media into which carefully controlled ratios of glucose, 
lactose and glycerol are added. Unlike IPTG induction glucose is not in excess in 
autoinduction media, this means that during E.coli culture growth glucose is depleted 
meaning cells must switch to lactose metabolism – when this occurs recombinant expression 
of the modified lacZ gene occurs. This diauxic switch is controlled on an individual cell basis 
meaning cells in culture only start producing recombinant protein when they are ready 
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producing a much more natural induction, in addition because glucose in the media depletes 
cAMP levels rise activating CRP. 
As stated previously ‘Manual’ IPTG induction did not seem to work with either form of 
Bd2325 produced for this study, however a switch to autoinduction did seem to improve the 
expression of both proteins. We attribute this improvement to the gentler induction of 
recombinant expression that autoinduction can produce.  Even though the use of 
autoinduction did not allow us to purify either form of Bd2325 it nonetheless improved some 
properties of the protein post expression, thus in future studies refinement of the 
autoinduction could be the route to the expression of soluble Bd2325. For instance by 
changing the ratio of glucose to lactose in the autoinduction media one can alter the point at 
which the lacZ cloned gene is activated – optimisation of this time point such that it occurs 
exactly when the E.coli cells are ready to express could improve the  outcome of the 
expression. 
4.2 Bd1971 
Bd1971 manual induction 
Unlike Bd2325, manual induction using IPTG did not seem to hinder the solubility or 
expression of Bd1971 (Figure 8) – instead the protein had problems with stability in solution 
meaning it could not be handled post purification without causing precipitation.  
Bd1971 autoinduction 
Once again switching from manual induction to autoinduction seemed to improve some 
properties of Bd1971. Using autoinduction the stability of Bd1971 improved significantly 
meaning that although we did not manage to crystallise the purified protein we did manage to 
perform some preliminary analytical tests to elucidate some of its properties. In addition we 
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managed to obtain a much higher yield of recombinant protein using autoinduction compared 
to IPTG induction. 
An intriguing explanation for the increased stability of Bd1971 following autoinduction could 
be linked to our findings that Bd1971 interacts with cAMP (Figure 11). As discussed 
previously, during E.coli’s diauxic switch from glucose to lactose, a rise in intracellular 
cAMP occurs which helps to induce expression of the lacZ gene via CRP. This rise in cAMP 
is likely to be mirrored during autoinduction when the E.coli exhausts the limited glucose in 
the media. It could be this spike in intracellular cAMP helps to stabilise Bd1971 via the 
putative interactions observed in this study. This is of course assuming that Bd1971 interacts 
with cAMP and that this interaction somehow promotes protein stability. With this in mind, it 
is conceivable that the high levels of cAMP produced during autoindction remains associated 
with Bd1971 during lysate preparation and IMAC purification – thus improving the stability 
of purified Bd1971. Corroborating this theory is the fact that recombinant Bd1971 obtained 
via IPTG induction was less stable, if our theory is correct this fits because IPTG induction 
does not produce the same cellular spike in cAMP, this is because IPTG induction is 
performed in glucose rich conditions and therefore the cAMP starvation response is not 
reproduced as it is in autoinduction. 
Purified Bd1971 - protein analysis 
Putative findings from analyses using analytical ultracentrifuge (AUC) suggest that Bd1971 
can exist as either a monomer or dimer in solution, and interestingly switches between the two 
conformations when cAMP is introduced to the sample. Due to the preliminary nature of our 
current data we cannot confidently state whether cAMP induces dimer formation from 
Bd1971 monomers, or conversely induces monomer formation from naturally forming 
Bd1971 dimers. The data from our preliminary AUC analysis suggests that cAMP may induce 
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dimer formation because the addition of cAMP seems to increase the ~ 90 kDa population in 
solution which is the weight inferred for a Bd1971 dimer. Conflicting data from an 
experiment performed by Dr A Lovering using small angle x-ray diffraction however suggests 
that the natural state of Bd1971 in solution is in a dimer and cAMP induces monomer 
formation. In view of the uncertainty produced by these conflicting data sets, and the inherent 
aggregative nature of purified Bd1971 and the interference of glycerol in the sample buffer 
we can currently only conclude that cAMP may change the oligomeric state of Bd1971.   
It will be essential in the future to ascertain the correct contribution of cAMP to Bd1971 
quaternary structure if we are to fully understand the function of Bd1971. This will firstly 
require establishment of how exactly cAMP changes the oligomerisation of Bd1971 – e.g. 
dimer to monomer or monomer to dimer. Following this work it will be also be important to 
ascertain whether cAMP binds to the N-terminal cAMP receptor like domain previously 
discussed. If it does in fact bind to this domain it is possible that cAMP acts as an allosteric 
regulator of Bd1971 C-di-GMP hydrolysis. If Bd1971 is allosterically regulated by cAMP it is 
possible that the switch in oligomeric state may play a role. Oligomeric state switches have 
been been shown to improve EAL phosphodiesterase activity in another EAL protein called 
YkuI from Bacillus subtillis (Minasov et al., 2009) where dimerisation is induced from 
protein monomers. Conversely to this example, a naturally forming Bd1971 dimer could be 
inactive until cAMP binding breaks it apart into active monomers.  
Bd1971 and cAMP  
Compelling evidence which would likely clear up any uncertainties as to the relationship 
between Bd1971 quaternary structure and cAMP could be gained by obtaining a crystal 
structure for Bd1971, especially if a crystal could be formed with cAMP and or C-di-GMP 
bound in situ. Our preliminary attempts to crystallise Bd1971 in this study were not 
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successful – for every condition tried we observed either no crystal formation or protein 
precipitation. It must be noted however these attempts were made before we discovered that 
Bd1971 may interact with to cAMP. With this in mind it is possible that a repeat of the 
crystallisation screening with additional cAMP or C-di-GMP added to the purified protein 
sample could provide the stability needed for formation of an ordered crystalline structure. 
This crystal could give us information as to whether cAMP does bind to Bd1971 and also 
where on the protein it binds, if the protein is crystallised in a dimerised form we could also 
determine what areas of the protein are involved in dimerisation and whether cAMP is 
implicated in this process.   
If the interaction between cAMP and Bd1971 can be established it will contribute to existing 
research which is gradually revealing close links between cAMP and C-di-GMP signalling 
systems in bacteria. An example of this link between the two signalling system comes from 
the bacteria Vibrio cholerae where it was found that cAMP was a negative regulator of 
biofilm formation and worked in opposition to C-di-GMP which positively regulated biofilm 
formation. Most significantly however was the discovery that cAMP directly controlled the 
activity of diguanylate cyclase and phosdiesterase enzymes within V. cholerae  via 
transcriptional regulation (Fong and Yildiz, 2008). This V. cholerae study is especially 
relevant to our study because initial phenotypic knockout experiments examining Bd1971’s 
functional role in B. bacteriovorus suggest that its knockout leads to biofilm like pellicle 
formation. With this in mind it is possible that a theme has evolved in the bacterial world 
whereby specific cAMP and C-di-GMP signalling systems work together to control switches 
between the formation and dispersal of bacterial biofilms. It is therefore possible that Bd1971 
– which has a potential role in B. bacteriovorus biofilm formation – is affected by the cAMP 
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starvation response, in this way perhaps cAMP can help to trigger a less energy intensive 
form of lifecycle in B. bacteriovorus when energy sources such as glucose are low.    
4.3 Conclusion 
In conclusion to our study we have firstly improved upon existing methods for the expression 
and purification of our two B. bacteriovorus proteins – Bd2325 and Bd1971. The 
improvements we recommend include the use of autoinduction expression technqiues to 
facilitate improved recombinant expression as well as the use of different expression 
constructs – e.g. truncation of Bd2325LF.  In addition to these experimental optimisations we 
also present the first successful isolation of recombinant Bd1971 from E.coli expression 
cultures and initial analysis of its properties. In this respect we have identified a potential 
interaction between cAMP and Bd1971, more specifically we suggest that this interaction 
may result in an oligomeric change between a monomer and dimer formation in solution. 
Although these findings are exciting we realise that further work must be done in order to 
establish and expand upon what we have found. In this respect we hope that the findings 
presented here, and any future findings which may come as a result of this study contribute in 
some way to our understanding of the unusual predacious bacterium Bdellovibrio 
bacteriovorus and its place in the bacterial kingdom as an important utiliser of C-di-GMP 
signalling. 
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